НАНЕСЕННЫЙ НА ЛЕНТУ ПРЕПАРАТ ДЛЯ ЧРЕСКОЖНОГО ВВЕДЕНИЯ, СОДЕРЖАЩИЙ ФЕНТАНИЛ

Описывается нанесенный на ленту препарат для чрескожного введения, содержащий соль фентанила - фентанилцитрат, чувствительный к давлению адгезив и ацетат натрия. Этот препарат обладает малой раздражающей способностью по отношению к коже и превосходной чрескожной проницаемостью и имеет высокую стабильность даже по прошествии времени. 6 з.п.ф-лы, 3 табл.

СТАБИЛЬНАЯ КОМПОЗИЦИЯ, ВКЛЮЧАЮЩАЯ ФАКТОР РОСТА ЭПИДЕРМИСА В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА

Изобретение относится к медицине, в частности к стабильной композиции, которая включает фактор роста эпидермиса (далее упоминается как "EGF") в качестве активного ингредиента и карбоксивиниловый полимер в качестве основы. Установлено, что препарат EGF, включающий EGF в качестве активного ингредиента и кислотный полимер, такой как карбоксивиниловый полимер, в качестве основы, обладает значительной стабильностью. Таким образом, композиция по настоящему изобретению является пригодной в качестве офтальмологических композиций, композиции для местного применения на коже, косметических композиций и т.п. 9 з.п. ф-лы, 6 табл.

СПОСОБ НЕПРЕРЫВНОГО ПОЛУЧЕНИЯ ТРАНСДЕРМАЛЬНОГО ПЛАСТЫРЯ НА ОСНОВЕ ПОЛИИЗОБУТИЛЕНА

Изобретение относится к способу получения адгезивной композиции без использования растворителя, к адгезивной композиции, не содержащей наполнителей и полученной вышеуказанным способом. Способ включает а) подачу высокомолекулярного полиизобутилена (ВММ PIB) в экструдирующее устройство, где указанный BMM PIB по существу не содержит наполнителей, растворителей и пластификаторов; b) смешивание указанного BMM PIB с низкомолекулярным полиизобутиленом (НММ PIB) в указанном экструдирующем устройстве для образования расплава, не содержащего по существу наполнителей, растворителей и пластификаторов; с) добавление активного фармацевтического ингредиента (API) к указанному расплаву для получения расплава API/PIB; и d) пропускание указанного расплава API/PIB через головку для образования указанной адгезивной композиции, не содержащей по существу наполнителей, растворителей и пластификаторов. Технический результат - способ получения адгезивной композиции для производства чувствительных к давлению клейких ...

ПРЕПАРАТ В ВИДЕ ПЛАСТЫРЯ

Изобретение относится к медицине. Описан препарат в виде пластыря, который имеет клеевой слой, по меньшей мере, на одной поверхности подложки, в котором клеевой слой содержит клей, плохорастворимое лекарственное средство, первый органический жидкий компонент, второй органический жидкий компонент, третий органический жидкий компонент и сшитый поливинилпирролидон. Растворимость плохорастворимого лекарственного средства в первом органическом жидком компоненте не меньше, чем растворимость плохорастворимого лекарственного средства во втором органическом жидком компоненте, и растворимость плохорастворимого лекарственного средства во втором органическом жидком компоненте не меньше чем растворимость плохорастворимого лекарственного средства в третьем органическом жидком компоненте. Препарат в виде пластыря имеет маленькую площадь и обеспечивает адгезию в течение длительного времени. 3 з.п. ф-лы, 1 ил., 3 табл., 10 пр.

АДГЕЗИВНЫЙ ПРЕПАРАТ

Изобретение относится к медицине. Описан адгезивный препарат, содержащий поддающуюся растягиванию основу и адгезивный слой, нанесенный тонким слоем по меньшей мере на одну сторону основы, где поддающаяся растягиванию основа содержит соединительный слой тканого материала, подвергнутый процессу гофрирования, адгезивный слой содержит 10% по массе или более метилсалицилата, из расчета на общую массу слоя, влагопроницаемость всего адгезивного препарата составляет 1-350 г/м2·24 часа, измеренную при температуре 40°С и относительной влажности 90%, и метилсалицилат имеет AUC0-24 в плазме в интервале от 3,0 до 60,0 нг·час/мл в значениях среднего ± стандартное отклонение, салициловая кислота в качестве метаболита метилсалицилата имеет AUC0-24 в плазме в интервале от 5000 до 13000 нг·час/мл в значениях среднего ± стандартное отклонение, когда адгезивный препарат накладывают на кожу человека на 8 часов, таким образом, что накладываемое количество адгезивного слоя составляет 50-300 г/м2, и площадь контакта ...

КЛЕЙКИЕ ЛЕКАРСТВЕННЫЕ ФОРМЫ

Изобретение относится к медицине. Описана клейкая лекарственная форма, включающая подложку и самоклеящийся клейкий слой, который содержит лекарственное средство и нанесен, по меньшей мере, на одну из сторон подложки; где подложка состоит из полиэфирной пленки, имеющей толщину от 0,5 до 6,0 мкм, и полиэфирного нетканого материала, непосредственно связанного с пленкой. Самоклеящийся клейкий слой непосредственно или через промежуточный слой нанесен на подложку со стороны нетканого материала. Клейкий препарат обладает достаточной гибкостью, чтобы соответствовать форме кожи, а также обладает пониженной способностью раздражать кожу и высокой устойчивостью. 6 з.п. ф-лы, 5 табл., 7 пр.

УСТРОЙСТВО ДЛЯ ТРАНСДЕРМАЛЬНОГО ВВЕДЕНИЯ БИСОПРОЛОЛА

Настоящее изобретение относится к медицине, конкретно к устройству для трансдермального введения бисопролола, которое включает в себя основу и слой чувствительного к давлению адгезива, содержащий бисопролол, который наслаивают на одну поверхность основы, где максимальное значение скорости высвобождения бисопролола в период времени непосредственно от нанесения на кожу до истечения 24 часов составляет 30 мкг/см2/час или меньше и где скорость высвобождения бисопролола через 24 часа после нанесения на кожу составляет 10 мкг/см2/час или меньше. Устройство для трансдермального введения снижает раздражение кожи, особенно при отслаивании, и может постоянно вводить в живой организм терапевтически или профилактически эффективное количество бисопролола. 4 з.п. ф-лы, 3 табл., 3 ил.

СИСТЕМЫ И СПОСОБЫ ДЛИТЕЛЬНОГО ТРАНСДЕРМАЛЬНОГО ВВЕДЕНИЯ

Группа изобретений относится к области трансдермальных систем доставки. Трансдермальный пластырь содержит первый покровный слой, состоящий из эластичного материала; стыковочный клейкий слой; второй покровный слой, состоящий из сегментов, которые по меньшей мере частично разделены; клейкий слой с действующим веществом, состоящий из сегментов, которые по меньшей мере частично разделены, и содержащий по меньшей мере одно действующее вещество; контактный клейкий слой; защитное покрытие; и причем контактный клейкий слой расположен между клейким слоем с действующим веществом и защитным покрытием. Также раскрывается способ трансдермального введения действующего вещества. Группа изобретений обеспечивает оказание долговременной или пролонгированной трансдермальной доставки действующего вещества. 2 н. и 20 з.п. ф-лы, 9 ил., 1 табл., 5 пр.

ПРЕПАРАТЫ ДЛЯ ЧРЕСКОЖНОЙ И ЧРЕССЛИЗИСТОЙ ДОСТАВКИ

Изобретение относится к медицине. Описаны препараты для чрескожного и/или чресслизистого всасывания, содержащие гидроксиапатит и активные ингредиенты. Гидроксиапатит имеет максимальный размер частиц 1 мкм или меньше, предпочтительно 0,1 мкм или меньше, и содержание гидроксиапатита по отношению к лекарственному средству, которое будет включено в композицию, составляет от 0,1 до 1000 мас.%. Препараты имеют превосходный эффект усиления чрескожного и/или чресслизистого всасывания активных ингредиентов при наложении на кожу или слизистую оболочку. 3 н. и 21 з.п. ф-лы, 11 табл.

СПОСОБ ПОДАВЛЕНИЯ ВЫЦВЕТАНИЯ СО ВРЕМЕНЕМ АДГЕЗИВНОЙ КОМПОЗИЦИИ, СОДЕРЖАЩЕЙ ДОНЕПЕЗИЛ

Изобретение относится к медицине. Описана донепезил адгезивная композиция, содержащая донепезил. По меньшей мере один вид стабилизатора, выбранного из группы, состоящей из аскорбиновой кислоты, металлической соли или сложного эфира таковой, изоаскорбиновой кислоты или металлической соли таковой, этилендиаминтетрауксусной кислоты или металлической соли таковой, 2-меркаптобензимидазола, 3(2)-трет-бутил-4-гидроксианизола, 2,6-ди-трет-бутил-4-метилфенола, тетракис[3-(3′,5′-ди-трет-бутил-4′-гидроксифенил)]пропионата пентаэритрита, (±)-α-токоферола, (±)-α-токоферолацетата, рутина, гипофосфорной кислоты, метабисульфитной соли металла и металлической соли гидроксиметансульфиновой кислоты, примешивают в слой приклеивающегося при надавливании клеевого средства, который содержит отверждаемое под давлением клеевое средство и донепезил. Содержащая донепезил адгезивная композиция подавляет выцветание с течением времени. 2 з.п. ф-лы, 3 табл.

АДГЕЗИВНЫЙ ПЛАСТЫРЬ, СОДЕРЖАЩИЙ БИСОПРОЛОЛ

Изобретение относится к медицине. Описан адгезивный пластырь, где каждый из элементов подложки, защитной пленки и адгезивного слоя имеет прямоугольную плоскую форму, и выступающая часть образована на поверхности со стороны подложки адгезивного пластыря по его углу. Кроме того, адгезивный пластырь может быть образован, чтобы иметь среднюю часть и периферийную часть, и выступающая часть может быть образована по углу прямоугольной средней части. Дополнительно, между смежными, по меньшей мере, двумя выступающими частями может быть предоставлена соединительная составная часть, в которой толщина адгезивного пластыря является меньшей, чем толщина адгезивного пластыря в выступающей части. Пластырь предотвращает просачивание наружу бисопролола или его соли из адгезивного слоя, предотвращая посредством этого снижение содержания лекарственного средства. 5 з.п. ф-лы, 6 ил., 4 табл., 8 пр.

ЛЕЙКОПЛАСТЫРЬ

Изобретение относится к медицине. Описан лейкопластырь, включающий растяжимую подложку и клеевой слой, нанесенный по меньшей мере на одну сторону подложки, в котором растяжимая подложка включает в себя тканый материал, вязаный чулочной вязкой на обеих сторонах, содержащих два или более рядов извитых мультифиламентных нитей из полиэтилентерефталата, клеевой слой содержит от 25 до 50% мас. жидкого органического ингредиента и от 25 до 50% мас. термопластичного эластомера по отношению к общей массе слоя и содержит 10% мас. или более метилсалицилата в качестве жидкого органического ингредиента по отношению к общей массе слоя, и динамический модуль упругости (G') клеевого слоя составляет от 30000 до 75000 Па при 10 рад/с и 37°С. Лейкопластырь обладает улучшенными свойствами высвобождения лекарства и впитыванием через кожу. 6 з.п. ф-лы, 6 ил., 6 табл.

НЕ СОДЕРЖАЩАЯ ВОЛОКНО ЧРЕСКОЖНАЯ ТЕРАПЕВТИЧЕСКАЯ СИСТЕМА И СПОСОБ ЕЕ ИЗГОТОВЛЕНИЯ

Изобретение относится к медицине, конкретно к чрескожной терапевтической системе (ЧТС), которая не содержит волокнистые компоненты, и способу изготовления такой чрескожной терапевтической системы, в котором содержащий действующее вещество препарат способом запечатывания наносят на склеивающий при надавливании клейкий слой чрескожной терапевтической системы. ЧТС почти не видимы на коже, поскольку сквозь них виден естественный цвет кожи пользователя. 11 з.п. ф-лы.

ТРАНСДЕРМАЛЬНАЯ ТЕРАПЕВТИЧЕСКАЯ СИСТЕМА С ВЫСОКИМ УРОВНЕМ ИСПОЛЬЗОВАНИЯ АКТИВНОГО ВЕЩЕСТВА И ТОЧНОСТЬЮ ДОЗИРОВАНИЯ

Изобретение относится к медицине. Описана трансдермальная терапевтическая система для введения фармацевтически активного вещества, нелетучего по меньшей мере при комнатной температуре, с суточной дозой не более 30 мг, включающая внешний слой, не соприкасающийся с кожей и непроницаемый для активного вещества, смежный - дальний от кожи, полимерный слой на основе полиизобутиленов с весом нанесенного покрытия по меньшей мере 80 г/м2, прилегающий к нему клеящий полимерный слой, контактный с кожей, на основе акрилатных сополимеров с весом нанесенного покрытия не более 50 г/м2, а также непроницаемый для активного вещества защитный слой, (легко) удаляемый с контактного с кожей слоя. Трансдермальная терапевтическая система имеет повышенный показатель использования активного компонента и более высокую точность дозирования. 2 н. и 16 з.п. ф-лы, 2 пр.

ЧРЕСКОЖНЫЕ ТЕРАПЕВТИЧЕСКИЕ СИСТЕМЫ, СОДЕРЖАЩИЕ ПОЛОВЫЕ СТЕРОИДЫ

Изобретение относится к медицине. Описываются чрескожные терапевтические системы, содержащие половые стероиды и в случае необходимости усилители пенетрации и ингибиторы кристаллизации, которые отличаются тем, что они содержат диметилизосорбид, за исключением систем, которые содержат включающие биологически активное вещество, нетекучие гель-фазы или 3-кето-дезогестрел. Данные системы обладают равномерной скоростью пенетрации стероидных гормонов через кожу. 2 с. и 11 з.п. ф-лы, 3 ил., 3 табл.

ЧУВСТВИТЕЛЬНАЯ К ДАВЛЕНИЮ СИСТЕМА ТРАНСДЕРМАЛЬНОЙ ДОСТАВКИ ЛЕКАРСТВА И СПОСОБ ЕЕ ПОЛУЧЕНИЯ

Группа изобретений относится к чувствительной к давлению системе трансдермальной доставки лекарства и способу ее получения и может использоваться для проникновения лекарственного средства из системы и через дерму. Система включает полимерный материал с введенным в него лекарством и представляет собой чувствительный к действию давления адгезив. Полимерный материал включает смесь полиакрилата и второго полимера. Второй полимер выбран из группы, состоящей из полиоилоксана и углеводородного полимера. Комбинация полиакрилата и второго полимера имеет общий параметр растворимости. Параметр растворимости модулирует скорость проникновения лекарства через кожу. Способ получения системы включает стадии гомогенизации лекарства в полимерном материале и формирования из смеси чувствительной к давлению адгезивной системы. Усовершенствованные способ и система позволяют избирательно включать лекарственное средство в дермальные системы и регулировать скорость проникновения лекарства из системы через дерму ...

САМОКЛЕЯЩАЯСЯ ЧРЕСКОЖНАЯ МАТРИЧНАЯ СИСТЕМА И СПОСОБ ЕЕ ПОЛУЧЕНИЯ

Изобретение относится к медицине, а именно к чрескожной матричной системе для чрескожного введения гормона, при этом матричная система имеет подложку и самоклеящуюся матрицу, которая включает матрицу, содержащую 20 - 42 мас. ч. трехблочного сополимера поли (стирол-изопрен-стирола), 35 - 55 мас.ч. смолы, повышающей клейкость, 5 - 25 мас.ч. пластификатора, выбранного из группы, состоящей из олеинового спирта, пегликоль-5-олеата, пропиленгликольлаурата или полипропоксилового эфира цетилового спирта, 5 - 15 мас.ч. по крайней мере одного соединения, выбранного из группы, состоящей из кротаматона и N-замещенных 2-пирролидонов формулы I где R представляет (C1 - C15)-алкильную, циклогексильную или 2-гидроксиэтильную группу, 0,01 - 1 мас.ч. стабилизатора и 0,1 - 5 мас.ч. гормона, выбранного из группы, состоящей из эстрогеновых компонентов, прогестогеновых компонентов и их смесей. Способ получения упомянутой системы включает смешение компонентов, затем гомогенизацию полученной смеси, с последующим ...

КОМПОЗИЦИЯ ДЛЯ ЧРЕСКОЖНОЙ ДОСТАВКИ ЛЕКАРТВЕННОГО СРЕДСТВА (ВАРИАНТЫ), СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ИСПОЛЬЗОВАНИЕ

... 1. Композиция для чрескожной доставки лекарственного средства, содержащая терапевтически эффективное количество лекарственного средства, включающего исходное лекарственное средство и пролекарство, каждое из которых присутствует в количестве, достаточном для достижения фармакологического действия, и фармацевтически приемлемый носитель. 2. Композиция по п.1, характеризующаяся тем, что она имеет более длинный или более короткий период до начала терапевтического действия по сравнению с композицией, содержащей фармакологически эквивалентное количество идентичных исходного лекарственного средства или пролекарства в отдельности. 3. Композиция по п.1, характеризующаяся тем, что она обеспечивает уровень содержания лекарственного средства в крови, который отличается от такового при использовании композиции, содержащей фармацевтически эквивалентное количество идентичных исходного лекарственного средства или пролекарства в отдельности. 4. Композиция по п.1, характеризующаяся тем, что она имеет более ...

АДГЕЗИВНАЯ КОМПОЗИЦИЯ

... 1. Адгезивная композиция, содержащая: гидрофобный полимер; высокоэластичный пластификатор; повышающую клейкость смолу; гидрофильный полимер; дополнительный полимер, способный к образованию водородных связей с гидрофильным полимером; и частицы глины. 2. Композиция по п.1, в которой гидрофобный полимер выбирают из полиизобутиленов, бутилкаучуков, адгезивов на основе натурального каучука, полимеров простого винилового эфира, полисилоксанов, полиизопренов, стирол-изопрен-стирольных блок-сополимеров, стирол-бутадиен-стирольных блок-сополимеров, изобутилен-изопреновых сополимеров, бутадиен-акрилонитрильного каучука, полихлоропренов, этилен-пропилен-диеновых терсополимеров, акрилатов и их комбинаций. 3. Композиция по п.2, в которой гидрофобный полимер выбирают из полиизопренов, бутилкаучука, стирол-изопрен-стирольных блок-сополимеров и стирол-бутадиен-стирольных блок-сополимеров. 4. Композиция по п.1, в которой высокоэластичный пластификатор выбирают из пластификаторов на основе стирола, полиизобутиленов ...

ТРАНСДЕРМАЛЬНАЯ ТЕРАПЕВТИЧЕСКАЯ СИСТЕМА, СОДЕРЖАЩАЯ АЗЕНАПИН И ПОЛИСИЛОКСАН ИЛИ ПОЛИИЗОБУТИЛЕН

ПРЕПАРАТ В ВИДЕ ПЛАСТЫРЯ

... 1. Препарат в виде пластыря, имеющий клеевой слой, по меньшей мере, на одной поверхности подложки, ! в котором указанный клеевой слой включает клей, плохорастворимое лекарственное средство, первый органический жидкий компонент, второй органический жидкий компонент, третий органический жидкий компонент и сшитый поливинилпирролидон, ! растворимость указанного плохорастворимого лекарственного средства в указанном первом органическом жидком компоненте не меньше, чем растворимость указанного плохорастворимого лекарственного средства в указанном втором органическом жидком компоненте, и ! растворимость указанного плохорастворимого лекарственного средства в указанном втором органическом жидком компоненте не меньше, чем растворимость указанного плохорастворимого лекарственного средства в указанном третьем органическом жидком компоненте. ! 2. Препарат в виде пластыря по п.1, в котором указанный первый органический жидкий компонент представляет собой первый многоатомный спирт, указанный второй органический ...

НЕ СОДЕРЖАЩАЯ ВОЛОКНО ЧРЕСКОЖНАЯ ТЕРАПЕВТИЧЕСКАЯ СИСТЕМА И СПОСОБ ЕЕ ИЗГОТОВЛЕНИЯ

... 1. Способ изготовления чрескожной терапевтической системы, отличающийся тем, что ! непроницаемый для действующего вещества несущий слой или необязательно присутствующий резервуарный слой или матричный слой снабжают не содержащим волокно склеивающим при надавливании клейким слоем, ! на склеивающий при надавливании клейкий слой способом запечатывания наносят разделенные на индивидуальные дозы части текучего содержащего действующее вещество препарата, при этом упомянутый текучий содержащий действующее вещество препарат содержит полимер, также являющийся компонентом склеивающего при надавливании клейкого слоя, и ! на последующей стадии на склеивающий при надавливании клейкий слой, снабженный содержащим действующее вещество препаратом, наносят непроницаемый для действующего вещества не содержащий волокно задний слой, ! при этом ЧТС может быть выделена из полученного к тому времени слоистого композита путем резки и/или перфорирования до или после нанесения содержащего действующее вещества препарата ...

ОПИПРАМОЛОВЫЙ ПЛАСТЫРЬ

КОМПОЗИЦИЯ ДЛЯ ЧРЕСКОЖНОГО ВСАСЫВАНИЯ

ПЛАСТЫРЬ, СОДЕРЖАЩИЙ ЭКСТРАКТ ЛУКА

СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ БОЛИ, ВКЛЮЧАЮЩИЕ ТРАНСДЕРМАЛЬНЫЕ КОМПОЗИЦИИ НА ОСНОВЕ ДЕКСМЕДЕТОМИДИНА

УПАКОВКА ДЛЯ САМОКЛЕЯЩЕЙСЯ АДГЕЗИВНОЙ ЛЕНТЫ

... 1. Упаковка для самоклеящейся адгезивной ленты, вмещающая адгезивную ленту, имеющую подложку и слой адгезивного средства, выполненный на одной поверхности подложки, причем упаковка для самоклеящейся адгезивной ленты содержит антиадгезионный лист, прикрепленный с возможностью отсоединения к слою адгезивного средства, при этомантиадгезионный лист согнут с образованием первого участка и второго участка вдоль заданной первой линии сгиба,адгезивная лента согнута с образованием первого участка и второго участка вдоль заданной второй линии сгиба так, что слой адгезивного средства обращен наружу, исогнутая адгезивная лента запечатана внутри согнутого антиадгезионного листа.2. Упаковка для самоклеящейся адгезивной ленты по п.1, в которой согнутая адгезивная лента запечатана внутри согнутого антиадгезионного листа в состоянии, в котором первая линия сгиба и вторая линия сгиба являются смежными друг другу.3. Упаковка для самоклеящейся адгезивной ленты по п.2, в которойпервый участок антиадгезионного ...

Пролонгатор для медицинского пластыря-клонидина

3-l-MENTHOXY-PROPANE-1, 2-DIOL ALS LÖSUNGSVERMITTLER UND EXTERNE ZUBEREITUNG, DIE DIESEN ENTHÄLT

MATRIX FÜR TRANSDERMALE WIRKSTOFFFREISETZUNG

ARZNEIMITTELBESTANDTEILE EINSCHLIESSLICH EINES N-SUBSTITUIERTEN O-TOLUIDINDERIVATS UND TRANSDERMAL ABSORBIERBARE ZUBEREITUNG

PFLASTER ZUR EXTERNEN ANWENDUNG

TRANSDERMALES ESTRADIOL ALS THERAPEUTISCHES SYTEM.

Transdermales therapeutisches System zur Verabreichung von Physostigmin an die Haut und Verfahren zu dessen Herstellung

Described is a transdermal therapeutic system for administering physostigmin through the skin, the system comprising a back film which is impermeable to the active substance, an adhesive reservoir layer containing 40 to 90 % by wt. of polymer material and 0.1 to 20 % by wt. of physostigmin base or one of its pharmaceutically acceptable salts, plus a detachable protective film covering the reservoir layer. The reservoir layer contains acrylate and/or methacrylate polymer material plus 0.1 to 40 % by wt. of a plasticizer containing hydroxyl groups and having an HLB value between 1.1 and 12.0.

Trägermaterial für medizinische Zwecke

The invention relates to supporting material for medicinal purposes. The supporting material is characterized in that it is a non-woven material which is topstitched with sewing threads and which has a maximum tensile strength of at least 10 N/cm. In addition, the supporting material is partially or completely coated on at least one side with a doped adhesive material.

Transdermal therapeutic system for administration of fenoterol and formoterol, useful for treating obstructive respiratory disorders

A transdermal therapeutic system (TTS) comprises a carrier foil, an adhesive layer containing dissolved or suspended fenoterol or formoterol as the base or a salt and a protective foil.

ARZNEIFILM MIT ANTIANGINALER WIRKUNG

TRANSDERMALES MATRIXSYSTEM

PFLASTER-ZUBEREITUNGEN ZUR TRANSDERMALEN ABSORPTION

Transdermale Verabreichung von (R)-3,3-Diphenylpropylamin-Monoestern

Die Erfindung betrifft eine Vorrichtung zur transdermalen Verabreichung einer Verbindung der Formel I, DOLLAR F1 in der A die Bedeutung von Wasserstoff oder Deuterium hat, R für eine Gruppe steht, die ausgewählt ist aus C¶1-6¶-Alkyl, C¶3-10¶-Cycloalkyl oder Phenyl, die jeweils mit C¶1-3¶-Alkoxy, Fluor, Chlor, Brom, Iod, Nitro, Amino, Hydroxy, Oxo, Mercapto oder Deuterium substituiert sein kann, wobei das mit "*" (Stern) markierte C-Atom in (R)-Konfiguration vorliegt, DOLLAR A dadurch charakterisiert, dass die Verbindung der allgemeinen Formel I in einer Polymerschicht vorliegt und in einer Dosis von 0,5-20 mg pro Tag durch Humanhaut freigesetzt wird. DOLLAR A Die Erfindung betrifft ferner die Verwendung der besagten Verbindungen der Formel I zur Herstellung transdermaler Arzneimittel.

Adhäsive Pflaster

Carrier material for medical applications, preferably for transdermal therapeutic system, has aluminum film between carrier and self-adhesive coating

The invention relates to a self-adhesive support material for medical applications, consisting of a support which is provided with an adhesive layer. The invention is characterised in that the support comprises an aluminium layer, which lies between the support and the self-adhesive layer.

Transdermal patch

Patch containing non-steroidal anti-inflammatory drug

Skin permeation enhancer compositions using glycerol monooleate

A method for enhancing the flux of transdermally deliverable drugs through intact skin is described in which the drug is delivered simultaneously with glycerol monooleate. Preferred embodiments of therapeutic systems for delivering drug and glycerol monooleate employ matrix containing drug at a concentration above saturation.

Novel formulations for transdermal delivery of pergolide

Composition of matter for application to a body surface or membrane to administer pergolide by permeation through the body surface or membrane, the composition comprising pergolide to be administered, at a therapeutically effective rate, alone or in combination with a permeation enhancer or mixture. Also disclosed are drug delivery devices containing the pergolide or pergolide and enhancer composition and methods for the transdermal administration of the pergolide and pergolide/enhancer composition.

PHARMACEUTICAL PRESSURE-SENSITIVE ADHESIVE PRODUCTS CONTAINING NITROGLYCERIN

Block copolymer

Transdermal delivery system comprising buprenorphine

Tamper-resistant oral opioid agonist formulations.

Disclosed is an oral dosage form comprising (i) an opioid agonists in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the amount of antagonist released from said dosage form after tampering to the amount of said antagonist released from said intact dosage form is about 4:1 or greater, based on the in-vitro dissolution at 1 hour of said dosage form in 900ml of Simulated Gastric Fluid using a USP Type II (paddle) apparatus at 75 rpm at 37 degrees C wherein said agonist and antagonist are interdispersed and are not isolated from each other in two distinct layers.

TRANSDERMAL DELIVERY SYSTEM COMPRISING BUPRENORPHINE

Tamper-resistant oral opioid agonist formulation

Propynylaminoindan transdermal compositions

TRANSDERMAL THERAPEUTIC SYSTEMS WITH CRYSTALLIZATION-INHIBITING PROTECTIVE FILM (RELEASE LINER)

Transdermal delivery system comprising buprenorphine

TRANSDERMAL DELIVERY SYSTEM

Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)

Propynylaminoindan transdermal compositions

Tamper-resistant oral opioid agonist formulations.

Propynylaminoindan transdermal compositions

Tamper-resistant oral opioid agonist formulation

TRANSDERMAL DELIVERY SYSTEM

Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)

Propynylaminoindan transdermal compositions

Transdermal delivery system comprising buprenorphine

Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)

TRANSDERMAL DELIVERY SYSTEM

Tamper-resistant oral opioid agonist formulation

PLASTER FOR OUTWARD APPLICATION

NEW FORMULATIONS FOR TRANSDERMALEN THE ADMINISTRATION OF PERGOLID

ACTIVE SUBSTANCES APPROXIMATELY PRURITUS TO THE OUTWARD USE

TRANSDERMALES THERAPEUTIC SYSTEM WITH HOCHDISPERSEM SILICON DIOXIDE

HORMONHALTIGES TRANSDERMALES THERAPEUTIC SYSTEM WITH AN ACTIVE SUBSTANCE RESERVOIR ON THE BASIS COHERENCE IMPROVED BY VINYL ACETATE VINYLPYRROLIDON COPOLYMER WITH.

PLASTER AND PLASTER PRODUCTION

TWO-PHASE, WATER-ABSORBING BIOADHÄSIVE ZUSAMMENSTEZUNG

ENTZÜNDUNGSHEMMENDES ANALGESIC FOR THE EXTERIOR APPLICATION

IMPROVED DRUG DELIVERY IN TRANSDERMALEN SYSTEMS

[...]pLASTER MIT [...] FOR USE IN TREATING PAIN FOR A dOSAGE - iNTERVAL OF 7 DAYS FOLLOWING THE

PHYSOSTIGMIN DERIVATIVES, YOUR USE AND IT ABSTENTION PHARMACEUTICAL FORMULATIONS

PRESSURE-SENSITIVE ADHESIVE COMPOSITION FROM POLY (N-VINYL LACTAM), PROCEDURES FOR YOUR PRODUCTION AND USE

TRANSDERMALES THERAPEUTIC SYSTEM WITH THE ACTIVE SUBSTANCE TULOBUTEROL.

TRANSDERMALES DRUG.

OESTROGENHALTIGES GEL PREPARATION.

PROCEDURE FOR THE PREVENTION OF THE EDUCATION OF A CRYSTALLINE HYDRATE IN A DISPERSION OF A LIQUID IN A NICHTWAESSRIGEN MATRIX.

TRANSDERMALES THERAPEUTIC SYSTEM WITH NORPSEUDOEPHEDRIN AS AN ACTIVE COMPONENT.

ARTICLE FOR THE TRANSDERMALE APPLICATION OF ESTRADIOL AND PROCEDURES FOR THE PRODUCTION OF SUCH AN ARTICLE.

TRANSDERMALES THERAPEUTIC SYSTEM TO THE DELIVERY OF 17--G (B) - ESTRADIOL AND PROCEDURES FOR ITS PRODUCTION

ACTIVE SUBSTANCE DELIVERY SYSTEMS.

SOLVENT-FREELY PRODUCIBLE ACTIVE SUBSTANCE PLASTER CONTAINING VOLATILE INGREDIENTS

ESTRADIOL TTS WITH WATER-BINDING ADDITIVES

ACTIVE SUBSTANCE PLASTER FOR LOWMELTING AND/OR VOLATILE ACTIVE SUBSTANCES

DEVICE TO THE RELEASE OF MATERIALS

TRANSDERMALE ABSORPTION OF ACTIVE SUBSTANCES FROM UNDERCOOLED MELTS

WITH MEDICINE MATERIAL PENETRATION ACCELERATOR OF COMPATIBLE OF PRESSURE-SENSITIVE BONDING EMULSIONS

PENETRATION-PROMOTING SUBSTANCES FOR THE TRANSDERMALE ADMINISTRATION FROM ACTIVE SUBSTANCES, DEVICES AND PROCEDURES TO THE PRODUCTION

ON A SOLUBILITY PARAMETER BASING MEDICINE DELIVERY SYSTEM AS WELL AS PROCEDURE FOR THE CHANGE OF THE SÄTTIGUNGSKONZENTRATION OF A MEDICINE

PROCEDURE FOR THE PRODUCTION OF A PLANAR FORMATION WITH A DETENTION ADHESIVE FOR THE SKIN

PREPARATIONS FOR APPLICATION AS PENETRATION PROMOTERS IN TRANSDERMALEN DRUGS THE HIGH-LIPOPHILIC ACTIVE SUBSTANCES CONTAINING

Antiviral transdermal patch and method for producing the same

An antiviral transdermal patch including a backing layer, a viscous polymer layer, and a protection film layer. The viscous polymer layer includes an antiviral agent, a viscous polymer, and a transdermal enhancer. The transdermal enhancer is laurocapram or a mixture thereof. The antiviral agent is a nucleoside antiviral drug with a daily delivery rate of less than 100 mg/day. The patch effectively promotes the penetration of a nucleoside antiviral agent into the blood circulation and avoids enzymolysis in the gastrointestinal tract and the first pass effect of the liver and reduces side effect of drugs, thereby inhibiting the replication of target viruses and reducing viral DNA level in the serum. A method for producing the patch is also provided. The raw materials involved in the invention are easily purchased from the market at a low cost.

Transdermal drug delivery device including an occlusive backing

A transdermal drug delivery system for the topical application of one or more active agents contained in one or more polymeric and/or adhesive carrier layers, proximate to a non-drug containing polymeric backing layer which can control the delivery rate and profile of the transdermal drug delivery system by adjusting the moisture vapor transmission rate of the polymeric backing layer.

Percutaneous absorption type plaster

A transdermal patch comprising a backing 2 and an adhesive layer 3 laminated on the backing 2 , wherein the adhesive layer 3 comprises a rosin-based resin and petroleum resin as a tackifier, the total compounding amount of the rosin-based resin and the petroleum resin is in a range of 15% by mass to 50% by mass, and compounding amount of the petroleum resin is 1/3 times by mass to 4 times by mass as that of the rosin-based resin.

Transdermal delivery patch

A composition suitable for use in a transdermal delivery patch for administration of a biologically active compound, the composition comprising a phosphate compound of tocopherol and a polymer carrier.

Transdermal therapeutic system for administration of fentanyl or an analog thereof

Disclosed is a transdermal therapeutic system for administering an active ingredient through the skin comprising: a) a back layer, b) a reservoir on the back layer comprising b1) a first layer containing active ingredient, at least one gel former, at least one plasticizer, and a first polyisobutylene; and b2) a second layer containing active ingredient, at least one gel former, at least one plasticizer, and a second polyisobutylene, wherein the first polyisobutylene is different from the second polyisobutylene, wherein at least the first layer contains undissolved active ingredient in the form of active ingredient particles; and wherein the active ingredient is fentanyl or an analogue of the fentanyl.

Transdermal therapeutic systems containing 4-n-butylresorcinol

Transdermal therapeutic systems that contain 4-n-butylresorcinol as an active ingredient.

Percutaneous absorption preparation comprising anti-dementia drug

The present invention relates to a percutaneous absorption preparation that is lower skin irritation and enables efficient transdermal administration of an anti-dementia drug. More specifically, the present invention relates to a percutaneous absorption preparation comprising an anti-dementia drug, a polymer compound having an amino group, a polyvalent carboxylate ester, a fatty acid alkyl ester, a styrenic polymer compound, and a tackifier resin.

Piroxicam-Containing Transdermally Absorbable Preparation

An adhesive patch is provided in which piroxicam is formulated as a non-steroidal anti-inflammatory analgesic. In particular, provided is a piroxicam-containing transdermally absorbable adhesive patch in which an absorption promoter to piroxicam is formulated to achieve high anti-inflammatory and analgesic effects without inhibiting releasing of these drugs. The piroxicam-containing transdermally absorbable adhesive patch contains piroxicam as a medicinal component and oxybuprocaine or a pharmaceutically acceptable salt thereof as an absorption promoter. In the piroxicam-containing transdermally absorbable adhesive patch, the content of piroxicam is from 0.1% to 5% by weight to the total weight of a drug-containing plaster and the content of oxybuprocaine or the pharmaceutically acceptable salt thereof is from 1% to 30% by weight to the total weight of the drug-containing plaster.

Transdermal Delivery Systems for Sufentanil

Transdermal delivery systems for administering sufentanil through the skin are provided. The systems contain a sufficient amount of sufentanil to induce and maintain a constant state of analgesia when applied to a subject. The systems are characterized as having one or more features including a high degree of dosage form rate control over flux of sufentanil from the system, a high net flux of sufentanil from the system through the skin, lack of a permeation enhancer, an adhesive member demonstrating superior shear time, a low coefficient of variation in the net flux of sufentanil from the system, a high delivery efficiency, and a substantially constant steady state net flux of sufentanil from the system. Methods of using the transdermal delivery systems to administer a sufficient amount of sufentanil to induce and maintain analgesia for extended periods when applied to a subject are also provided.

PATCH

Disclosed is a patch which is a formulation including deposited clonidine crystals and provides stable transdermal absorbability even after storage at varying temperatures. The patch disclosed includes a backing and a medicated layer integrally superposed on one surface of the backing. The medicated layer contains: 5 to 30% by weight of clonidine including clonidine in a crystallized state; 25 to 90% by weight of a macromolecular base (A) having a viscosity-average molecular weight of 800,000 or larger; and 5 to 60% by weight of a liquid additive capable of dissolving the clonidine. The weight ratio of the liquid additive to the macromolecular base (A) [the liquid additive/the macromolecular base (A)] is 0.1 to 2.0. 1. A patch comprising:a backing; anda medicated layer integrally superposed on one surface of the backing, the medicated layer containing: 5 to 30% by weight of clonidine including clonidine in a crystallized state; 25 to 90% by weight of a macromolecular base (A) having a viscosity-average molecular weight of 800,000 or larger; and 5 to 60% by weight of a liquid additive capable of dissolving the clonidine, and a weight ratio of the liquid additive to the macromolecular base (A) [the liquid additive/the macromolecular base (A)] being 0.1 to 2.0.2. The patch according to claim 1 , wherein the medicated layer contains 25 to 85% by weight of the macromolecular base (A).3. The patch according to claim 2 , wherein the medicated layer contains 1 to 69% by weight of the macromolecular base (B) having a viscosity-average molecular weight of 10 claim 2 ,000 or larger and less than 800 claim 2 ,000.4. The patch according to claim 1 , wherein the macromolecular base (A) includes a rubber-based adhesive or an alkyl (meth)acrylate copolymer having no polar functional group.5. The patch according to claim 1 , wherein the macromolecular base (A) includes polyisobutylene.6. The patch according to claim 1 , wherein the liquid additive includes liquid paraffin.7. The ...

Transdermal delivery systems

Disclosed are bupivacaine transdermal delivery systems, and related methods.

PATCH AND PATCH PREPARATION

The invention provides a patch and a patch preparation having an adhesive layer with a high adhesive force, wherein the hydrophobic adhesive layer does not bloom even when an organic fluid component having high polarity is contained therein. The patch contains a support and an adhesive layer on at least one surface of the support, wherein the adhesive layer contains a synthetic rubber having a viscosity average molecular weight of 1,700,000-6,500,000, an organic fluid component having high polarity, a tackifier, and magnesium aluminometasilicate. In the patch preparation, the above-mentioned adhesive layer further contains a drug. 1. A patch comprising a support and an adhesive layer on at least one surface of the support , wherein the adhesive layer comprises a synthetic rubber having a viscosity average molecular weight of 1 ,700 ,000-6 ,500 ,000 , an organic fluid component having high polarity , a tackifier , and magnesium aluminometasilicate.2. The patch according to claim 1 , wherein the organic fluid component having high polarity has an angle within the range of 20°-80° as calculated by the following formula using an inorganic value and an organic value in an organic conceptual diagram:{'br': None, 'sup': '−1', 'Angle[°]=arctan(organic value/inorganic value)×(180/π)'}3. The patch according to claim 1 , wherein the content of the organic fluid component having high polarity in the adhesive layer is not more than 20 wt % relative to the total weight of the adhesive layer.4. The patch according to claim 1 , further comprising an organic fluid component having low polarity which shows lower polarity than the organic fluid component having high polarity.5. The patch according to claim 4 , wherein the organic fluid component having low polarity has an angle within the range of 0°-19° as calculated by the following formula and using an inorganic value and an organic value in an organic conceptual diagram:{'br': None, 'sup': '−1', 'Angle[°]=arctan(organic value/ ...

METHOD FOR PRODUCING PATCH, AND PATCH

A method for producing a patch including a support layer and an adhesive layer, comprising the step of forming the adhesive layer with use of an adhesive layer composition obtained by mixing an alkali metal diacetate, a drug, and a nonaqueous adhesive base such that the molar ratio between the drug and the alkali metal diacetate (the number of moles of the drug:the number of moles of the alkali metal diacetate) is from 1:0.5 to 1:15. 1. A method for producing a patch comprising a support layer and an adhesive layer , the method comprising forming the adhesive layer from an adhesive layer composition obtained by mixing an alkali metal diacetate , a drug , and a nonaqueous adhesive base , wherein a molar ratio between the drug and the alkali metal diacetate , calculated as a of moles of the drug to a number of moles of the alkali metal diacetate , is from 1:0.5 to 1:15.2. The method of claim 1 , wherein the alkali metal diacetate is sodium diacetate.3. The method of claim 1 , wherein the drug is an acid addition salt of a basic drug.4. The method of claim 1 , wherein the drug is a polybasic acid addition salt or hydrochloric acid addition salt of a basic drug.5. The method of claim 1 , wherein the drug is at least one selected from the group consisting of a fumaric acid addition salt of a basic drug claim 1 , a maleic acid addition salt of a basic drug claim 1 , a citric acid addition salt of a basic drug claim 1 , and a hydrochloric acid addition salt of a basic drug.6. The method of claim 3 , wherein the basic drug is at least one selected from the group consisting of emedastine claim 3 , setiptiline claim 3 , and oxybutynin.7. The method of claim 1 , wherein the nonaqueous adhesive base is at least one selected from the group consisting of a styrene-isoprene-styrene block copolymer claim 1 , a (meth)acrylate (co)polymer claim 1 , polyisobutylene claim 1 , and a silicone polymer.8. A patch comprising a support layer and an adhesive layer claim 1 , wherein the ...

Transdermal Therapeutic System Provided With Improved Long-Term Carrying Comfort

The invention relates to transdermal therapeutic systems (TTS) comprising a backing, a reservoir layer containing at least one pharmaceutical active ingredient, and an adhesive. Said transdermal therapeutic systems are characterised in that they are able to continuously adhere to the surface of the skin over a long period of time. During said long period of time, a) there is at least one time interval during which the TTS adhering to the surface of the skin is intensively exposed to water, and b) the active ingredient is transdermally released. The invention also relates to a method for the continuous transdermal release of at least one pharmaceutical active ingredient over a long period of time.

Transdermal pharmaceutical formulations for the treatment of multiple sclerosis

The present disclosure relates to the to the transdermal administration of THC and/or CBD and derivatives of these compounds, for the treatment and/or prevention and/or control of multiple sclerosis, multiple sclerosis-related muscle spasms, and pain and/or spasticity in multiple sclerosis.

USE OF BULLEYACONITINE A

The present disclosure belongs to the field of pharmaceuticals. Disclosed is a use of bulleyaconitine A in treating pruritus or a secondary lesion thereof, especially pruritus induced by histamine and/or chloroquine. 1. A method of treating and/or preventing skin pruritus and/or a secondary lesion thereof , comprising administering bulleyaconitine A to a subject in need thereof.2. The method according to claim 1 , wherein a dosage of bulleyaconitine A is 0.125 mg/kg mouse body weight/d−0.5 mg/kg mouse body weight/d.3. The method according to claim 1 , wherein a dosage of the bulleyaconitine A is 0.01375 mg/kg human body weight/d−0.055 mg/kg human body weight/d.4. The method according to claim 1 , wherein the skin pruritus is neuropathic itch.5. The method according to claim 4 , wherein the skin pruritus is an itch caused by histamine and/or chloroquine.6. The method according to claim 1 , wherein bulleyaconitine A is present in a medicament which comprises a pharmaceutically acceptable carrier claim 1 , and bulleyaconitine A is present in the medicament in an amount of 0.2%-88% by mass.7. The method according to claim 6 , wherein the medicament is in a dosage form of oral preparation claim 6 , injection preparation or external preparation.8. The method according to claim 7 , wherein the oral preparation includes hard capsules claim 7 , dripping pills claim 7 , granules claim 7 , tablets claim 7 , mixtures claim 7 , soft capsules claim 7 , concentrated pills claim 7 , oral solutions or powders.9. The method according to claim 7 , wherein the injection preparation is injection solution or lyophilized powder for injection.10. The method according to claim 7 , wherein the external preparation is tincture claim 7 , ointment claim 7 , cream claim 7 , paste claim 7 , aerosol claim 7 , spray claim 7 , powder claim 7 , otic preparation claim 7 , lotion claim 7 , rinse claim 7 , liniment claim 7 , paint claim 7 , film preparation claim 7 , gelatin or patch. This application ...

TRANSDERMAL PATCH PROVIDING IMPROVED PERMEABILITY AND COMPOSITION

A transdermal patch contains a water-based solution containing electrolytes, vitamins, and at least one permeation enhancer. The water-based solution also acts as an adhesive matrix which binds the patch together. The solution is transferred to the body via an embossed release liner. In use, the permeation of electrolytes into the bloodstream improves the body's ability to manage hydration. The permeation enhancer increases the porosity of the skin in contact with the transdermal patch to make possible the permeation of the solution into the body. Critical proportions of solvent, solutes, and permeation enhancers are disclosed which have been found to make permeation of otherwise non-absorbable ingredients possible. 1. A transdermal patch comprising:a backer;an embossed release liner able to contact skin; and water,', 'electrolytes,', 'vitamins,', 'an adhesive agent, and', 'a permeation enhancer comprising menthol., 'an adhesive matrix binding the embossed release liner to the backer, the adhesive matrix containing'}2. The transdermal patch of claim 1 , wherein the permeation enhancer further comprises dimethyl sulfoxide.3. The transdermal patch of claim 1 , wherein the permeation enhancer comprises peppermint oil.4. The transdermal patch of claim 1 , wherein the adhesive matrix comprises between ten percent and thirty percent water.5. The transdermal patch of claim 1 , wherein the adhesive matrix comprises polysorbate 80.6. The transdermal patch of claim 1 , wherein the adhesive agent comprises one or more ofsodium polyacrylate;polyacrylic acid;carboxymethylcellulose; andpovidone.7. The transdermal patch of claim 1 , wherein the backer claim 1 , the embossed liner claim 1 , and the adhesive matrix in combination comprise a perimeter forming a water-drop shape.8. The transdermal patch of claim 1 , wherein the adhesive matrix further comprises an external analgesic.9. The transdermal patch of claim 1 , wherein the transdermal patch comprises a thickness of between 0. ...

TRANSDERMALLY ABSORBABLE PREPARATION

The present invention provides a transdermal absorption preparation in which a drug-containing adhesive layer is formed on a support, the aforementioned adhesive layer contains at least a thermoplastic elastomer and a higher fatty acid ester, and a content of a tackifier is not more than 10 wt %, which is superior in drug solubility and releasability, as well as adhesiveness to the skin and low irritation to the skin. 1. A transdermal absorption preparation comprising a support and a drug-containing adhesive layer formed on the support , wherein the drug-containing adhesive layer comprises a thermoplastic elastomer and a higher fatty acid ester ,a content of the higher fatty acid ester in the drug-containing adhesive layer is more than 50 parts by weight and not more than 500 parts by weight per 100 parts by weight of the thermoplastic elastomer, anda content of a tackifier in the drug-containing adhesive layer is not more than 10 wt % (0 wt % inclusive) relative to a total amount of the drug-containing adhesive layer.2. The transdermal absorption preparation according to claim 1 , wherein a higher fatty acid in the higher fatty acid ester has a carbon number of not less than 12 and not more than 30.3. The transdermal absorption preparation according to claim 1 , wherein the thermoplastic elastomer comprises a styrene-based block copolymer.4. The transdermal absorption preparation according to claim 3 , wherein the styrene-based block copolymer is a styrene-isoprene-styrene block copolymer.5. The transdermal absorption preparation according to claim 1 , wherein the drug-containing adhesive layer does not contain a tackifier.6. The transdermal absorption preparation according to claim 1 , wherein the drug-containing adhesive layer comprises polyisobutylene.7. The transdermal absorption preparation according to claim 1 , wherein the drug-containing adhesive layer comprises donepezil or a salt thereof as the drug.8. The transdermal absorption preparation according to ...

BUTORPHANOL-CONTAINING PATCH

A patch comprising: 1. A patch comprising:a backing layer; andan adhesive layer, whereinthe adhesive layer contains at least one drug selected from the group consisting of butorphanol and pharmaceutically acceptable salts thereof and a silicone-based adhesive base, and{'sup': '2', 'a mass per unit area of the adhesive layer is 30 to 90 g/m.'}2. The patch according to claim 1 , whereinthe adhesive layer further contains at least one absorption enhancer selected from the group consisting of aliphatic alcohols and fatty acid esters.3. The patch according to claim 2 , whereinthe absorption enhancer is at least one selected from the group consisting of isostearyl alcohol, oleyl alcohol, octyldodecanol, and propylene glycol monolaurate.4. The patch according to claim 2 , whereina content of the absorption enhancer in the adhesive layer is 2:1 to 1:4 in a mass ratio of butorphanol and/or the pharmaceutically acceptable salt thereof (mass of butorphanol and/or the pharmaceutically acceptable salt thereof in terms of a tartaric acid addition salt of butorphanol:mass of the absorption enhancer).5. The patch according to claim 2 , whereina content of the absorption enhancer in the adhesive layer is 1.5 to 25% by mass relative to a total mass of the adhesive layer.6. The patch according to claim 1 , whereina content of butorphanol and/or the pharmaceutically acceptable salt thereof in the adhesive layer is 3 to 9% by mass relative to the total mass of the adhesive layer in terms of a tartaric acid addition salt of butorphanol.7. The patch according to claim 1 , whereina content of the silicone-based adhesive base in the adhesive layer is 50 to 97% by mass relative to the total mass of the adhesive layer.8. The patch according to claim 1 , whereinthe adhesive layer further contains an adsorbent.9. The patch according to claim 8 , whereina content of the adsorbent in the adhesive layer is 3:1 to 1:4 in a mass ratio of butorphanol and/or the pharmaceutically acceptable salt ...

Base Composition for Tape Agent

The present invention provides a composition for a non-aqueous patch preparation having an excellent adhesibility which can sustainedly release a drug. The patch preparation of the present invention can improve the adhesibility thereof as well as the release property of a drug by the addition of powder ingredient (e.g. a filler). As a result, the long-time sustention of the adhesibility of patch preparations can achieve the improvement of the transdermal absorbability and the sustained release of a drug. By the use of a composition for a patch preparation comprising this powder ingredient, a drug, regardless of the type of a drug is dissolved in an organic solvent or an ionic liquid to prepare a drug solution comprising the organic solvent, the drug solution is incorporated into the non-aqueous patch preparation of the present invention, and thereby a preparation with the improved transdermal-absorbability and sustained release can prepared. 1. A composition for a non-aqueous patch preparation comprising a drug , an organic solvent , and a powder which is insoluble both in the organic solvent and in a lipophilic plaster base material , wherein the powder for an adhesive layer is contained as shown in the following inequality:{'br': None, '0.2×(the weight of the adhesive layer)×(the bulk density of the powder)≤the amount of the powder to be added≤0.6×(the weight of the adhesive layer)×(the tap density of the powder).'}2. The composition according to claim 1 , wherein the powder is at least one selected from the group consisting of crystalline cellulose claim 1 , anhydrous silicic acid claim 1 , starch claim 1 , carmellose claim 1 , carmellose metal salt claim 1 , kaolin claim 1 , agar claim 1 , carrageenan claim 1 , pectin claim 1 , and powdered sugar.3. The composition according to or claim 1 , wherein the powder is a mixture of powders.4. The composition according to any one of to claim 1 , wherein the organic solvent comprises a fatty acid-based ionic liquid and/ ...

COMPOSITION FOR ACCELERATING PENETRATION THROUGH SKIN, PREPARATION FOR TRANSDERMAL ADMINISTRATION, AND SKIN PATCH PREPARATION

The present invention provides a skin penetration-accelerating composition that eliminates the need for forming a drug into a particle structure and dramatically improves the skin penetration properties of a drug without breaking the skin tissue. The present invention also provides a preparation for transdermal administration containing the skin penetration-accelerating composition and a patch preparation containing the skin penetration-accelerating composition. The present invention provides a skin penetration-accelerating composition containing a flavonoid compound and used for accelerating skin penetration of a drug. 1. A skin penetration-accelerating composition comprising:a flavonoid compound,the composition being used for accelerating skin penetration of a drug.3. The skin penetration-accelerating composition according to claim 2 , wherein the compound having a flavone skeleton represented by Formula (1) is at least one compound selected from the group consisting of quercetin claim 2 , apigenin claim 2 , and myricetin.4. A preparation for transdermal administration comprising:a drug; and{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'the skin penetration-accelerating composition according to .'}5. A patch preparation comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'a drug-containing layer that contains a drug and the skin penetration-accelerating composition according to .'}6. The patch preparation according to claim 5 ,wherein the drug-containing layer is a drug-containing adhesive layer, andthe drug-containing adhesive layer is provided on one surface of a support. The present invention relates to a skin penetration-accelerating composition used for accelerating skin penetration of a drug. In particular, the present invention relates to a skin penetration-accelerating composition that eliminates the need for forming a drug into a particle structure and dramatically improves skin penetration properties of a drug without breaking the skin ...

METHOD FOR PRODUCING PATCH, PATCH AND PACKAGE

A method for producing a patch comprising a support layer and an adhesive agent layer arranged on at least one surface of the support layer, the method comprising: 1. A method for producing a patch comprising a support layer and an adhesive agent layer arranged on at least one surface of the support layer , the method comprising: free ropinirole in an amount which results in 5 to 13.2% by mass relative to a total mass of an obtained adhesive agent layer,', 'at least one compound selected from the group consisting of benzyl alcohol, oleyl alcohol, octyldodecanol, and dimethyl isosorbide in an amount of 5 to 50 parts by mass relative to 100 parts by mass of the free ropinirole,', 'at least one compound selected from the group consisting of isopropyl myristate isopropyl palmitate lauryl alcohol glycerin monooleate, propylene glylcol monolaurate, polyoxyethylene sorbitan monooleate, and lauric acid diethanolamide in an amount of 10 to 150 parts by mass relative to 100 parts by mass of the free ropinirole, and', 'a rubber-based adhesive agent in an amount which results in 15 to 35% by mass relative to the total mass of the obtained adhesive agent layer;, 'step A) obtaining an adhesive agent layer composition comprising'}step B) heating the adhesive agent layer composition at a temperature in a range from 50 to 76° C. for 5 minutes to 24 hours; andstep C) cooling the heated adhesive agent layer composition to normal temperature at an average rate of temperature drop of 1 to 20° C./hour, thereby obtaining the adhesive agent layer comprising the free ropinirole at a supersaturated concentration in a dissolved form.2. The method for producing a patch according to claim 1 , whereinthe adhesive agent layer composition further comprises at least one compound selected from the group consisting of benzyl alcohol, oleyl alcohol, octyldodecanol, and dimethyl isosorbide in an amount of 10 to 40 parts by mass relative to 100 parts by mass of the free ropinirole.3. The method for ...

Multi-polymer compositions for transdermal drug delivery

Multi-polymer compositions for the transdermal delivery of drugs, such as amine-functional drugs, in a flexible, finite form are described. The compositions comprise a polymer matrix that includes a drug or a pharmaceutically acceptable salt thereof and a polymer matrix comprising acrylic polymer(s), polyisobutylene polymer(s) and styrene-isoprene-styrene block copolymer(s). Methods of manufacturing and methods of using the compositions also are described.

Transdermal Delivery Systems

Disclosed are bupivacaine transdermal delivery systems, and related methods. 1. A transdermal delivery system , comprising:a backing layer; and bupivacaine; and', 'sucrose acetate isobutyrate present in an amount effective to reduce a peel force of the transdermal delivery system compared to a peel force of a transdermal delivery system comprising an otherwise identical pressure sensitive adhesive composition that does not comprise sucrose acetate isobutyrate., 'a pressure sensitive adhesive composition, comprising28.-. (canceled)9. A transdermal delivery system comprising:a backing layer, and{'sup': '2', 'a reservoir laminated to the backing layer that comprises bupivacaine in an amount ranging from about 0.1 to about 0.5 mg/cm; and'}wherein the reservoir is adapted to transdermally deliver the bupivacaine from the transdermal delivery system to a subject for a period such that the following mean plasma concentrations are achieved:{'sup': '2', 'a mean plasma concentration, normalized to an initial loading of the transdermal delivery system, ranging from about 0.0003 to about 0.7 cm/L at about 12 hours after initiation of the transdermal delivery; and'}{'sup': '2', 'a mean plasma concentration, normalized to an initial loading of the transdermal delivery system, ranging from about 0.0014 to about 0.4 cm/L at about 24 hours after initiation of the transdermal delivery.'}10. The transdermal delivery system of claim 9 , wherein the reservoir is further adapted to transdermally deliver the bupivacaine from the transdermal delivery system to a subject for a three day period such that the following mean plasma concentrations are achieved: a mean plasma concentration claim 9 , normalized to an initial loading of the transdermal delivery system claim 9 , ranging from about 0.0013 to 0.3 cm/L at about 48 hours after initiation of the transdermal delivery.11. The transdermal delivery system of claim 9 , wherein the reservoir is further adapted to transdermally deliver the ...

COMPOSITION FOR ACCELERATING PENETRATION THROUGH SKIN, PREPARATION FOR TRANSDERMAL ADMINISTRATION, AND SKIN PATCH PREPARATION

The present invention provides a skin penetration-accelerating composition that eliminates the need for forming a drug into a particle structure and dramatically improves the skin penetration properties of a drug without breaking the skin tissue. The present invention also provides a preparation for transdermal administration containing the skin penetration-accelerating composition and a patch preparation containing the skin penetration-accelerating composition. The present invention provides a skin penetration-accelerating composition containing a flavonoid compound and a surfactant and used for accelerating skin penetration of a drug. 1. A skin penetration-accelerating composition comprising:a flavonoid compound; anda surfactant,the composition being used for accelerating skin penetration of a drug.2. The skin penetration-accelerating composition according to claim 1 , wherein the flavonoid compound is a compound having a flavone skeleton and/or a compound having a isoflavone skeleton.3. The skin penetration-accelerating composition according to claim 2 , wherein the compound having a flavone skeleton is at least one compound selected from the group consisting of quercetin claim 2 , myricetin claim 2 , and chrysin claim 2 , and the compound having an isoflavone structure is genistein.4. A preparation for transdermal administration comprising:a drug; and{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'the skin penetration-accelerating composition according to .'}5. A patch preparation comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'a drug-containing layer that contains a drug and the skin penetration-accelerating composition according to .'}6. The patch preparation according to claim 5 , wherein the drug-containing layer is a drug-containing adhesive layer claim 5 , and the drug-containing adhesive layer is provided on one surface of a support. The present invention relates to a skin penetration-accelerating composition used for accelerating skin ...

TRANSDERMAL DELIVERY SYSTEM

The invention relates to transdermal therapeutic system for the transdermal administration of buprenorphine, comprising a buprenorphine-containing self-adhesive layer structure comprising A) a buprenorphine-impermeable backing layer, and B) a buprenorphine-containing pressure-sensitive adhesive layer on said buprenorphine-impermeable backing layer, the adhesive layer comprising a) at least one polymer-based pressure-sensitive adhesive, b) an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof, c) a viscosity-increasing substance in an amount of about 0.1% to about 8% of said buprenorphine-containing pressure-sensitive adhesive layer, and d) a carboxylic acid selected from the group consisting of oleic acid, linoleic acid, linolenic acid, levulinic acid and mixtures thereof, in an amount sufficient so that said analgesically effective amount of buprenorphine is solubilized therein to form a mixture including said viscosity-increasing substance, and wherein the carboxylic acid-, buprenorphine- and viscosity-increasing substance-containing mixture forms dispersed deposits in the said pressure-sensitive adhesive, and wherein said buprenorphine-containing pressure-sensitive adhesive layer is the skin contact layer. 163.-. (canceled)66. The transdermal therapeutic system of claim 65 , wherein said polyvinylpyrrolidone has a K-Value of at least about 5 claim 65 , or of at least about 10 claim 65 , or of at least about 15 claim 65 , or of at least about 20 claim 65 , or of at least about 50 claim 65 , or of at least about 80.67. The transdermal therapeutic system of claim 64 , wherein said buprenorphine is present in the form of buprenorphine base and/or wherein said carboxylic acid is levulinic acid.68. The transdermal therapeutic system of claim 64 , wherein said polymer-based pressure-sensitive adhesive is based on polysiloxanes or polyisobutylenes.69. The transdermal therapeutic system of claim 64 , wherein said ...

TRANSDERMAL DELIVERY SYSTEM CONTAINING GALANTAMINE OR SALTS THEREOF

Disclosed herein is a transdermal delivery system comprising galantamine or its salt as an active ingredient. Also provided are methods of delivering a therapeutically effective amount of galantamine to a subject for the treatment of a disease condition. The disease condition includes a neurological condition such as Alzheimer's disease. Kits including the transdermal delivery system and methods of making such delivery system are also provided. 1. A transdermal delivery system which comprises a drug-containing matrix layer comprising:(i) galantamine or its pharmaceutically acceptable salt;(ii) an adhesive comprising an acrylic polymer without a functional group or an acrylate-vinyl acetate polymer having at least one carboxyl functional group (COOH);(iii) an enhancer composition including: (a) oleyl oleate and oleic acid; (b) oleyl oleate and propylene glycol and an antioxidant; or (c) a medium chain fatty acid triglyceride and an antioxidant.2. The transdermal delivery system of claim 1 , wherein the medium chain fatty acid triglyceride comprises about 50-80% of caprylic acid and about 20-50% of capric acid.3. The transdermal delivery system of claim 1 , wherein the transdermal delivery system consists of a backing layer claim 1 , the drug-containing matrix layer claim 1 , and a release layer.4. The transdermal delivery system of claim 1 , wherein the galantamine or its pharmaceutically acceptable salt is about 7 to about 14% by weight based on the total weight of the drug-containing matrix layer.5. The transdermal delivery system of claim 4 , wherein the galantamine or its pharmaceutically acceptable salt is about 7 claim 4 , about 8 or about 14% by weight based on the total weight of the drug-containing matrix layer.6. The transdermal delivery system of claim 1 , wherein the adhesive is about 75-78% by weight based on the total weight of the drug-containing matrix layer.7. The transdermal delivery system of claim 1 , wherein the acrylic polymer has a glass ...

Topical and transdermal delivery of hif-1 modulators to prevent and treat chronic wounds

Compositions and methods are provided for the prevention and treatment of chronic wounds, including, without limitation, pressure ulcers and diabetic ulcers, by transdermal delivery of an agent that increases activity of HIF-1α in the wound.

Fibre-Free Transdermal Therapeutic System and Method for its Production

The present invention is directed to transdermal therapeutic systems that are free of fibrous constituents, as well methods for producing such transdermal therapeutic systems. A preparation containing active substance is applied by a printing method onto the pressure-sensitive adhesive layer of the transdermal therapeutic system. Exemplary printing methods include application methods based upon a distributor plate of an application device. 1. A method for producing a transparent transdermal therapeutic system comprising the steps of:providing a light-permeable, fiber-free pressure-sensitive adhesive layer;printing individually dosed portions of a flowable, active substance-containing preparation onto the light-permeable, fiber-free pressure-sensitive adhesive layer, said flowable active substance-containing preparation comprising a polymer which is also a constituent of the light-permeable, fiber-free pressure-sensitive adhesive layer to form a composite laminate; andapplying an active substance-impermeable, light-permeable, fiber-free backing layer onto the composite laminate of the printing step,forming singularised transparent transdermal therapeutic systems by at least one of cutting and punching following said step of applying the active substance-impermeable, light-permeable, fiber-free backing layer,and said printing method is a method comprising the step of transferring the active substance-containing preparation onto the light-permeable, fiber-free pressure-sensitive adhesive layer by a distributor plate of an application device, said distributor plate being provided with at least one passage.2. The method according to claim 1 , wherein said printing method is a pad printing method.3. The method according to claim 1 , wherein said polymer is selected from the group consisting of cationic copolymers based on dimethylaminoethyl methacrylate and neutral methacrylic esters claim 1 , and neutral copolymers based on butyl methacrylate and methyl methacrylates.4. ...

ADHESIVE PATCH

Disclosed is an adhesive patch having a support and an adhesive agent layer laminated on the support, wherein the support consists of spunlace nonwoven fabric, the adhesive agent layer comprises an SIS block copolymer and liquid paraffin, the adhesive patch has a first direction, which is a predetermined reference axis direction, and a second direction, which is orthogonal to the first direction, and a bending resistance in the first direction of the adhesive patch is 18 to 30 mm. 1. An adhesive patch comprising:a support; andan adhesive agent layer laminated on the support, whereinthe support consists of spunlace nonwoven fabric,the adhesive agent layer comprises a styrene-isoprene-styrene block copolymer and liquid paraffin,the adhesive patch has a first direction, which is a predetermined reference axis direction, and a second direction, which is orthogonal to the first direction, and a bending resistance in the first direction of the adhesive patch measured by a 45° cantilever method defined in JIS L 1085:1998 is 18 to 30 mm.2. The adhesive patch according to claim 1 , wherein a mass ratio of the styrene-isoprene-styrene block copolymer to the liquid paraffin in the adhesive agent layer is 1 to 1.65:1.3. The adhesive patch according to claim 2 , wherein the adhesive agent layer comprises methyl salicylate and menthol.4. The adhesive patch according to claim 3 , wherein the adhesive agent layer comprises polyisobutylene.5. The adhesive patch according to claim 4 , wherein the adhesive agent layer comprises a terpene resin.6. The adhesive patch according to claim 5 , wherein the adhesive agent layer comprises claim 5 , based on a total mass of the adhesive agent layer claim 5 , 9 to 11% by mass of methyl salicylate and 2.5 to 6.5% by mass of menthol.7. The adhesive patch according to claim 5 , wherein the adhesive agent layer comprises claim 5 , based on a total mass of the adhesive agent layer claim 5 , 23.7 to 32.5% by mass of the styrene-isoprene-styrene block ...

PATCH TO ENHANCE LOCALLY FAT METABOLISM, USING THERMOPLASTIC ELASTOMER GEL COMPOSITION INCLUDING CAPSAICIN

There is provided a patch to enhance locally fat metabolism, using a thermoplastic elastomer gel composition including capsaicin, which is applied to the skin surface, comprises: a skin adhering layer formed of the thermoplastic elastomer (TPE) gel including capsaicin, the skin adhering layer having a top surface and a bottom surface; a base layer secured to the bottom surface of the skin adhering layer, to support for the patch; and a removable paper/film layer secured to the top surface of the skin adhering layer, to protect the skin adhering layer prior to use, wherein the skin adhering layer comprises: 3˜12 wt % of styrene ethylene butylene styrene (SEBS) or styrene ethylene ethylene propylene styrene (SEEPS), 44˜53 wt % of an adhesive agent; 44˜53 wt % of mineral oil, and 0.001˜0.009 wt % of capsaicin. Capsaicin included in the TPE gel derives heat generation and fat breakdown, to help attain fat loss in the area where the patch is applied. 1. A patch to enhance locally fat metabolism , using a thermoplastic elastomer (TPE) gel composition including capsaicin , which is applied to the skin surface , comprising:a skin adhering layer formed of 3˜12 wt % of styrene ethylene butylene styrene (SEBS) or styrene ethylene ethylene propylene styrene (SEEPS), 44˜53 wt % of an adhesive agent; 44˜53 wt % of mineral oil, and 0.001˜0.009 wt % of capsaicin, the skin adhering layer having a top surface and a bottom surface;a base layer secured to the bottom surface of the skin adhering layer, to provide support for the patch; anda removable paper/film layer secured to the top surface of the skin adhering layer, to protect the skin adhering layer prior to use.2. The patch using a thermoplastic elastomer gel composition including capsaicin according to claim 1 , wherein the thickness of the skin adhering layer is 20˜400 μm3. The patch using a thermoplastic elastomer gel composition including capsaicin according to claim 1 , wherein the base layer is a non-woven fabric or ...

SODIUM BICARBONATE IN SITU CONVERSION DRIVEN TRANSDERMAL DELIVERY OF AMINE DRUG

Compositions, devices, and methods for transdermal administration of active agents provided in their salt form instead of neutral form are provided. 1. A transdermal delivery system , comprising:a drug reservoir comprising an amine salt form of donepezil and an amphoteric inorganic base compound selected from sodium bicarbonate and potassium bicarbonate, wherein the pKa of the amphoteric inorganic base compound is lower than that of the amine salt form of the active agent.2. The transdermal delivery system of claim 1 , wherein the amphoteric inorganic base compound is sodium bicarbonate.3. The transdermal delivery system of claim 1 , wherein the amine salt form of donezpezil is present in the drug reservoir in an amount between about 5-35% w/w.4. The transdermal delivery system of claim 1 , wherein the sodium bicarbonate is present in the drug reservoir in an amount between about 0.5-35% w/w.5. The transdermal delivery system of claim 1 , wherein the amine salt form of donezpezil is donepezil HCl claim 1 , and wherein the drug reservoir comprises a molar amount of donepezil HCl and a less than equimolar amount of sodium bicarbonate.6. The transdermal delivery system of claim 1 , wherein the drug reservoir further comprises a salt form solubilizer selected from the group consisting of water claim 1 , alcohols claim 1 , glycerol claim 1 , propylene glycol claim 1 , ethylene glycol claim 1 , dimethyl sulfoxide claim 1 , and N-methylpyrrolidone.7. The transdermal delivery system of claim 6 , wherein the salt form solubilizer is present in the drug reservoir in an amount of up to 15% w/w.8. The transdermal delivery system of claim 1 , wherein the drug reservoir further comprises a neutral form solubilizer selected from the group consisting of a fatty acid ester claim 1 , a dicarboxylic acid ester claim 1 , a glycerol ester claim 1 , a lactate claim 1 , and a fatty alcohol.9. The transdermal delivery system of claim 1 , wherein the drug reservoir further comprises a ...

Enhanced Drug Delivery from Adhesives

Various adhesive compositions are described which comprise one or more active agents such as pharmaceutical agents. The adhesive compositions exhibit enhanced release characteristics. The incorporation of one or more absorbents in particular proportions and/or in conjunction with certain components improves release and release characteristics of active(s). Also described are related methods of improving release of biologically active agents from adhesives and related methods of use of the compositions and articles using such compositions. 1. A method of releasing at least one active agent to a region of interest on biological skin , the method comprising:providing an article adapted for placement along biological skin, the article defining at least one face;providing an adhesive composition including an adhesive component, 0.1% to 50% of at least one absorbent, and 0.1% to 20% of at least one active agent;depositing the adhesive composition onto the face of the article;applying the article to a region of interest on biological skin, whereby the adhesive composition is directed toward and overlies the region of interest.2. The method of wherein the adhesive composition contacts at least a portion of the region of interest on biological skin.32. The method of any one of - wherein the absorbent is selected from the group consisting of (i) insoluble swellable polymers claims 1 , (ii) hydratable polymers claims 1 , (iii) water soluble polymers claims 1 , (iv) synthetic absorbents claims 1 , (v) super absorbent polymers claims 1 , and (vi) combinations of any one or more of (i)-(v).42. The method of any one of - wherein the absorbent is carboxymethyl cellulose.5. The method of wherein the carboxymethyl cellulose has a degree of substitution within a range from 0.2 to 1.5.65. The method of any one of - wherein the carboxymethyl cellulose has a molecular weight in a range from 17 claims 4 ,000 to 700 claims 4 ,000.76. The method of any one of - wherein the at least one ...

PATCH

The objective of the present invention is to provide a local anesthetic agent-containing patch having a skin permeability, cohesion force and adhesive property practical as a pharmaceutical product. The patch of the present invention is characterized in comprising a backing layer, and an adhesive layer on the backing layer, wherein the adhesive layer comprises at least a local anesthetic agent, a thermoplastic elastomer, a higher fatty acid ester, and a polyol fatty acid monoester, and a ratio of the higher fatty acid ester to 100 mass parts of the thermoplastic elastomer is 25 mass parts or more and 200 mass parts or less. 1. A patch comprising:a backing layer; andan adhesive layer on the backing layer, the adhesive layer comprising a local anesthetic agent, a thermoplastic elastomer, a higher fatty acid ester, and a polyol fatty acid monoester,wherein a ratio of the higher fatty acid ester to 100 mass parts of the thermoplastic elastomer is 25 mass parts or more and 200 mass parts or less.2. The patch according to claim 1 , wherein the ratio of the higher fatty acid ester to 100 mass parts of the thermoplastic elastomer is 30 mass parts or more and 150 mass parts or less.3. The patch according to claim 1 , wherein an amount of the higher fatty acid ester in the adhesive layer is 60 mass % or less.4. The patch according to claim 1 , wherein a carbon number in an ester part of the higher fatty acid ester is 12 or more and 30 or less.5. The patch according to claim 1 , wherein the thermoplastic elastomer is a styrene block copolymer.6. The patch according to claim 5 , wherein the styrene block copolymer is a mixture of a styrene-isoprene-styrene block copolymer and a styrene-isoprene block copolymer.7. The patch according to claim 6 , wherein a ratio of the styrene-isoprene block copolymer in the mixture is 50 mass % or more.8. The patch according to claim 5 , wherein a viscosity of a 25 mass % toluene solution of the styrene block copolymer at 25° C. is 500 mPa·s or ...

Therapeutic Preparations and Articles

A therapeutic preparation and article treated with tourmaline nano-particles and a method of manufacturing the same. The therapeutic preparation comprises a gel and tourmaline nano-particles held in suspension in said gel. The therapeutic article comprises a fabric and tourmaline particles attached to said fabric. In one embodiment, an adhesive containing tourmaline is applied to non-treated fabric to form the article. In another embodiment, the tourmaline is integral to the fabric. A method of manufacturing the therapeutic article comprises the steps of submerging a fabric in an aqueous solution comprising tourmaline nano-particles and drying said fabric. 1. A therapeutic preparation comprising:a binding agent; andtourmaline particles held in suspension in said binding agent.2. The therapeutic preparation of claim 1 , wherein said preparation is selected from a group comprising a gel claim 1 , a cream claim 1 , an ointment and a lotion.3. The therapeutic preparation of claim 1 , wherein said binding agent comprises propylene glycol.4. The therapeutic preparation of claim 1 , wherein the tourmaline particles have a diameter greater than 100 nanometers.5. The therapeutic preparation of claim 1 , wherein the tourmaline particles are selected from a group comprising black tourmaline claim 1 , white tourmaline and gray tourmaline.6. The therapeutic preparation of claim 1 , wherein a concentration of the tourmaline particles is about 20% of an overall volume of the therapeutic preparation.7. A therapeutic article comprising:a fabric; andtourmaline particles attached to said fabric.8. The therapeutic article of claim 7 , wherein the tourmaline particles are ionized into the fabric.9. The therapeutic article of claim 8 , wherein the article is ionized to about 500 ions per cubic centimeter.10. The therapeutic article of claim 7 , further comprising an adhesive applied to the fabric claim 7 , wherein the tourmaline particles are included in the adhesive.11. The therapeutic ...

Systems and methods for long term transdermal administration

Devices, systems, compositions and methods for long term or prolonged transdermal administration of an active agent are provided.

ADHESIVE SKIN PATCH

The present invention provides an adhesive skin patch containing a support and an adhesive layer containing a drug which is formed on the support, wherein the adhesive layer comprises a thermoplastic elastomer, a liquid component in an amount exceeding 300 parts by weight per 100 parts by weight of the thermoplastic elastomer, a therapeutic drug having an anticholinergic activity or a salt thereof for overactive bladder as a drug, (A) a non-volatile hydrocarbon oil as a liquid component, and one or more kinds selected from the group consisting of (B) an amide solvent, (C) an alcohol solvent and (D) a liquid organic acid as a liquid component, or a fatty acid salt, and optionally comprises a tackifier at a content of not more than 10 wt % of the adhesive layer. 1. An adhesive skin patch comprising a support and an adhesive layer containing a drug which is formed on the support , whereinthe adhesive layer comprisesa thermoplastic elastomer,a liquid component in an amount exceeding 300 parts by weight per 100 parts by weight of the thermoplastic elastomer,a therapeutic drug having an anticholinergic activity or a salt thereof for overactive bladder as a drug,(A) a non-volatile hydrocarbon oil as a liquid component, andone or more kinds selected from the group consisting of (B) an amide solvent, (C) an alcohol solvent and (D) a liquid organic acid as a liquid component, or a fatty acid salt, and optionally comprises a tackifier at a content of not more than 10 wt % of the adhesive layer.2. The adhesive skin patch according to claim 1 , wherein the therapeutic drug having an anticholinergic activity for overactive bladder is one or more kinds selected from the group consisting of solifenacin claim 1 , darifenacin and tolterodine.3. The adhesive skin patch according to claim 2 , wherein the adhesive layer comprises claim 2 , as the liquid component claim 2 , (B) an amide solvent and one or more kinds selected from the group consisting of (C) an alcohol solvent and (D) a ...

TRANSDERMAL FORMULATION AND DELIVERY METHOD OF LOW SOLUBILITY OR UNSTABLE UNIONIZED NEUTRAL DRUGS BY IN SITU SALT-TO-NEUTRAL DRUG CONVERSION OF SALT DRUG

Compositions, devices, and methods for transdermal administration of active agents provided in their salt form instead of neutral form are provided. 1. A composition for transdermal delivery , comprising:a drug reservoir comprising a salt form of an active agent and a proton accepting and/or proton donating entity.2. The composition of claim 1 , wherein the drug reservoir comprises an amine salt form of an active agent and a proton accepting entity.3. The composition of claim 1 , wherein the active agent is donepezil claim 1 , rivastigmine claim 1 , memantine claim 1 , or tamsulosin.4. The composition of claim 1 , wherein the drug reservoir comprises about 1% to about 70% w/w of the active agent.5. The composition of claim 2 , wherein the proton accepting entity is a proton accepting polymer.6. The composition of claim 2 , wherein the proton accepting entity is an amine functionalized polystyrene miscrosphere or a dimethyl aminoethyl methacrylate-based acrylate.7. The composition of claim 2 , wherein the drug reservoir comprises about 0.5% to about 35% w/w of the proton accepting entity.8. The composition of claim 1 , wherein the drug reservoir comprises an acid salt form of an active agent and a proton donating polymer.9. The composition of claim 8 , wherein the active agent is an acid salt drug selected from the group consisting of sodium alendronate claim 8 , tresprostinil sodium claim 8 , sodium diclofenac claim 8 , naproxen sodium claim 8 , and ketoprofen sodium.10. The composition of claim 8 , wherein the drug reservoir comprises about 5% to about 35% w/w of the active agent.11. The composition of claim 8 , wherein the proton donating polymer is an anionic copolymer based on methacrylic acid or a carboxylated polystyrene microsphere.12. The composition of claim 8 , wherein the drug reservoir comprises about 0.5% to about 35% w/w of the proton donating polymer.13. The composition of claim 1 , further comprising a salt form solubilizer selected from the group ...

ADHESIVE PATCH

Provided is an adhesive patch capable of exerting excellent tackiness when the adhesive patch is attached to the skin and having a low incidence of detachment from the skin during attachment. The adhesive patch of the present invention includes a support, and an adhesive layer integrally layered on one surface of the support, the adhesive layer containing an acrylic adhesive, a solid resin that is incompatible with the acrylic adhesive and is in a solid state at 40° C., a plasticizer, and a drug. The combined use of the solid resin and the plasticizer can simultaneously achieve the tackiness and cohesive force of the adhesive layer. 19-. (canceled)10. An adhesive patch comprising:a support; andan adhesive layer integrally layered on one surface of the support, the adhesive layer containing 100 parts by weight of an acrylic adhesive, 1 to 25 parts by weight of a solid resin that is incompatible with the acrylic adhesive and is in a solid state at 40° C., the solid resin containing at least one kind of resin selected from the group consisting of ethyl cellulose, a styrene-isoprene-styrene block copolymer, and a terpene resin, 5 to 80 parts by weight of a plasticizer containing at least one kind selected from the group consisting of octyldodecanol, isopropyl myristate, and a liquid paraffin, and 1 to 40 parts by weight of a liquid drug being in a liquid state at 30° C. and containing at least one kind of the liquid drug having a plasticization effect selected from the group consisting of rivastigmine, selegiline, and ethyl salicylate;{'sub': 1', '2', '1', '2, 'wherein a ratio by weight of a total amount of the plasticizer (P) and the liquid drug having a plasticization effect (P) to an amount of the solid resin (S) [(P+P)/S] is 1.5 to 25.'}11. The adhesive patch according to claim 10 , wherein a difference between a solubility parameter of the acrylic adhesive and a solubility parameter of the solid resin is 0.5 (cal/cm)or more.12. The adhesive patch according to claim ...

PERCUTANEOUS ABSORPTION PREPARATION COMPRISING STABILIZED DONEPEZIL

A percutaneous absorption preparation including donepezil for the treatment of dementia is disclosed. The percutaneous absorption preparation for the treatment of dementia includes a support layer, a drug-containing layer, and a release layer, wherein the drug-containing layer contains donepezil or a pharmaceutically acceptable salt thereof as an active ingredient; monothioglycerol, thiocyanate metal salt (preferably potassium salt) or dimethylthiourea as a stabilizer; and a pressure-sensitive adhesive. Also disclosed is a percutaneous absorption preparation for the treatment of dementia with reduced the formation of donepezil impurities. 1. A percutaneous absorption preparation comprising a support layer , a drug-containing layer , and a release layer , wherein:the drug-containing layer comprises donepezil or a pharmaceutically acceptable salt thereof as an active ingredient, and a stabilizer selected from the group consisting of monothioglycerol, thiocyanate metal salt, and dimethylthiourea.2. A percutaneous absorption preparation according to claim 1 , wherein the donepezil is in the form of a free base.3. A percutaneous absorption preparation according to claim 1 , wherein the thiocyanate metal salt used as a stabilizer is potassium thiocyanate.4. A method of preparing a percutaneous absorption preparation comprising donepezil claim 1 , wherein the method comprises the steps of:i) dissolving donepezil and monothioglycerol, thiocyanate metal salt, or dimethylthiourea in an organic solvent;ii) applying the solution obtained in step i) onto a release layer and drying to form a drug-containing layer; andiii) laminating the drug-containing layer obtained in step ii) with a support layer.5. The method of claim 4 , wherein the organic solvent is selected from the group consisting of ethyl acetate claim 4 , toluene claim 4 , hexane claim 4 , 2-propanol claim 4 , methanol claim 4 , ethanol claim 4 , methylene chloride claim 4 , and tetrahydrofuran. The present invention ...

Adhesive Properties

Various adhesive compositions are described which may optionally comprise one or more active agents such as pharmaceutical agents. The incorporation of one or more absorbents in combination with one or more crystallization inhibitors improves adhesive characteristics of the compositions. Also described are related methods of improving adhesive characteristics of adhesive compositions with the use of a combination of absorbent and inhibitor. Also described are related methods of using the compositions and articles incorporating such compositions.

TRANSDERMAL DRUG DELIVERY SYSTEMS FOR NORETHINDRONE ACETATE

Described are transdermal drug delivery systems for the transdermal administration of norethindrone acetate in the form of a flexible finite system for topical application, comprising a drug-in-adhesive polymer matrix comprising norethindrone acetate (NETA) as the only systemically active drug, an adhesive polymer selected from silicone adhesives and polyisobutylene (PIB) adhesives, a penetration enhancer, and a crystallization inhibitor. Methods of making and using the systems also are described. 1. A transdermal drug delivery system for the transdermal delivery of norethindrone acetate in the form of a flexible finite system for topical application , comprising a drug-in-adhesive polymer matrix comprising norethindrone acetate (NETA) as the only systemically active drug , an adhesive polymer selected from silicone adhesives and polyisobutylene (PIB) adhesives , a penetration enhancer , and a crystallization inhibitor.2. The transdermal drug delivery system of claim 1 , wherein the penetration enhancer is selected from the group consisting of oleyl alcohol claim 1 , dipropylene glycol claim 1 , isopropyl myristate claim 1 , glyceryl monooleate claim 1 , and combinations thereof.3. The transdermal drug delivery system of claim 2 , wherein the penetration enhancer comprises oleyl alcohol.4. The transdermal drug delivery system of claim 2 , wherein the penetration enhancer comprises oleyl alcohol and dipropylene glycol.5. The transdermal drug delivery system of claim 2 , wherein the penetration enhancer comprises oleyl alcohol and glyceryl monooleate.6. The transdermal drug delivery system of claim 2 , wherein the penetration enhancer comprises dipropylene glycol claim 2 , ispropyl myristate and glyceryl monooleate.7. The transdermal drug delivery system of claim 1 , wherein the crystallization inhibitor is selected from the group consisting of povidone claim 1 , polyvinylpyrrolidone (PVP) claim 1 , copovidone claim 1 , polyvinylpyrrolidone-vinyl acetate copolymer ( ...

PATCH

A method for suppressing a plasma concentration of an asenapine metabolite includes applying to a subject a patch comprising a support layer and an adhesive agent layer, the adhesive agent layer includes asenapine and/or a pharmaceutically acceptable salt thereof, and an adhesive base agent.

TRANSDERMAL PATCH FOR TREATMENT OF DEMENTIA OR ALZHEIMER TYPE DEMENTIA

Disclosed is a transdermal patch for treatment of degenerative neurological disorders like dementia or Alzheimer type dementia. More particularly, the transdermal patch for treatment of neurodegenerative disorder comprises an adhesive monolayer which comprises Rivastigmine in free base form or its pharmaceutically acceptable salts, styrene block copolymer, and a tackifier, wherein total styrene units are in an amount of 4% w/w or more of said adhesive monolayer. 1. A transdermal patch for treatment of neurodegenerative disorder of dementia or Alzheimer type dementia , comprising a backing film , an adhesive monolayer containing 10-25% of Rivastigmine in free base form or its pharmaceutically acceptable salts and a release liner , the adhesive monolayer further comprising styrene block copolymer and tackifiers , wherein total polystyrene units are in an amount of 4%-6% w/w of said adhesive monolayer.23-. (canceled)4. The transdermal patch as claimed in claim 1 , wherein said styrene block copolymer is in an amount of 10-35% w/w of said adhesive monolayer.5. (canceled)6. The transdermal patch as claimed in claim 4 , wherein said styrene block copolymer is selected from the group consisting of styrene-butadiene-styrene claim 4 , Styrene-ethylene/butylene-styrene claim 4 , Styrene-ethylene/propylene claim 4 , and Styrene-isoprene-styrene.7. The transdermal patch as claimed in claim 1 , wherein said tackifier is a combination of rosin ester and petroleum resin claim 1 , wherein the ratio of petroleum resin: rosin ester is 1:1 to 3:1.8. (canceled)9. The transdermal patch as claimed in claim 1 , wherein said tackifier is in an amount of 30-70% w/w claim 1 , of said adhesive monolayer.10. The transdermal patch as claimed in claim 7 , wherein the ratio of total tackifier: styrene block copolymer is 2:1 to 3:1.1114-. (canceled)15. The transdermal patch as claimed in claim 1 , wherein said backing film is selected from polyester film claim 1 , polyester/polyethylene lamination ...

Ultraviolet-hardening hydrogel resin and hydrogel for transdermal administration, and cataplasm agent containing same

The present invention relates to a UV-curable hydrogel resin for transdermal administration, a hydrogel prepared using the UV-curable hydrogel resin, and a cataplasm prepared using the UV-curable hydrogel resin. More particularly, the present invention relates to a hydrogel resin with an optimal composition and composition ratio which allows increase in a water content of a hydrogel applied as a drug layer of a cataplasm, skin irritation mitigation, and crosslinking degree adjustment for adhesion control and is capable of controlling drug releasing property and transdermal absorbability, a hydrogel prepared by UV-hardening the hydrogel resin, and a cataplasm including the hydrogel.

TRANSDERMAL DELIVERY SYSTEM COMPRISING DONEPEZIL OR ITS SALT

Provided is a transdermal delivery system consisting of a backing layer, a drug-containing matrix layer, and a release layer, wherein the drug-containing matrix layer includes (a) donepezil or a pharmaceutically acceptable salt thereof as an active ingredient, (b) a mixture of high molecular weight polyisobutylene having a weight-average molecular weight ranging from 400,000 to 3,000,000 and low molecular weight polyisobutylene having a weight-average molecular weight ranging from 25,000 to 300,000 as an adhesive, and (c) a permeation enhancer in not more than 3% by weight based on the total weight of the drug-containing matrix layer. 1. A transdermal delivery system consisting of a backing layer , a drug-containing matrix layer , and a release layer , wherein the drug-containing matrix layer comprises (a) donepezil or a pharmaceutically acceptable salt thereof as an active ingredient , (b) a mixture of high molecular weight polyisobutylene having a weight-average molecular weight ranging from 400 ,000 to 3 ,000 ,000 and low molecular weight polyisobutylene having a weight-average molecular weight ranging from 25 ,000 to 300 ,000 as an adhesive , and (c) a permeation enhancer in not more than 3% by weight based on the total weight of the drug-containing matrix layer.2. The transdermal delivery system of claim 1 , wherein donepezil or a pharmaceutically acceptable salt thereof is present in an amount of 5 to 10% by weight based on the total weight of the drug-containing matrix layer3. The transdermal delivery system of claim 1 , wherein the high molecular weight polyisobutylene has a weight-average molecular weight ranging from 800 claim 1 ,000 to 1 claim 1 ,500 claim 1 ,000.4. The transdermal delivery system of claim 1 , wherein the low molecular weight polyisobutylene has a weight-average molecular weight ranging from 25 claim 1 ,000 to 200 claim 1 ,000.5. The transdermal delivery system of claim 1 , wherein the adhesive is a mixture of high molecular weight ...

TRANSDERMAL DELIVERY SYSTEM COMPRISING BUPRENORPHINE

The invention relates to transdermal therapeutic system for the transdermal administration of buprenorphine, comprising a buprenorphine-containing self-adhesive layer structure comprising A) a buprenorphine-impermeable backing layer, and B) a buprenorphine-containing pressure-sensitive adhesive layer on said buprenorphine-impermeable backing layer, the adhesive layer comprising a) at least one polymer-based pressure-sensitive adhesive, b) an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof, and c) a carboxylic acid selected from the group consisting of oleic acid, linoleic acid and linolenic acid, levulinic acid and mixtures thereof, in an amount sufficient so that said analgesically effective amount of buprenorphine is solubilized therein to form a mixture, and the carboxylic acid buprenorphine mixture forms dispersed deposits in the said pressure-sensitive adhesive, wherein said buprenorphine-containing pressure-sensitive adhesive layer is the skin contact layer. 179.-. (canceled)80. A method of treating pain in a patient comprising applying a transdermal therapeutic system for the transdermal administration of buprenorphine to the skin of the patient , wherein the transdermal therapeutic system comprises a buprenorphine-containing self-adhesive layer structure comprisinga. a buprenorphine-impermeable backing layer, and i. at least one polymer-based pressure-sensitive adhesive,', 'ii. an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof, and', 'iii. a carboxylic acid selected from the group consisting of oleic acid, linoleic acid, linolenic acid, levulinic acid and mixtures thereof, in an amount sufficient so that said analgesically effective amount of buprenorphine is solubilized therein to form a mixture, and the carboxylic acid buprenorphine mixture forms dispersed deposits in the said pressure-sensitive adhesive,, 'b. a buprenorphine-containing pressure-sensitive ...

TRANSDERMAL PATCH CONTAINING ROPINIROLE

The present invention provides a patch comprising a backing and an adhesive agent layer laminated on the backing, wherein the adhesive agent layer comprises ropinirole or a pharmaceutically acceptable salt thereof, an organic amine or an acid addition salt thereof, and an adhesive agent. 1. A patch comprising:a backing; andan adhesive agent layer laminated on the backing,wherein the adhesive agent layer comprises ropinirole or a pharmaceutically acceptable salt thereof, an organic amine or an acid addition salt thereof, and an adhesive agent.2. The patch according to claim 1 , wherein the organic amine is at least one organic amine selected from the group consisting of monoethanolamine claim 1 , diethanolamine claim 1 , triethanolamine claim 1 , monoisopropanolamine claim 1 , diisopropanolamine and ethylenediamine.3. The patch according to claim 1 , wherein the adhesive agent comprises at least one adhesive agent selected from the group consisting of a rubber adhesive agent claim 1 , an acrylic adhesive agent and a silicone adhesive agent.4. The patch according to claim 1 , wherein the adhesive agent comprises a styrene-isoprene-styrene block copolymer.5. The patch according to claim 2 , wherein the adhesive agent comprises at least one adhesive agent selected from the group consisting of a rubber adhesive agent claim 2 , an acrylic adhesive agent and a silicone adhesive agent.6. The patch according to claim 2 , wherein the adhesive agent comprises a styrene-isoprene-styrene block copolymer. The present invention relates to a patch containing ropinirole.Ropinirole is a compound represented by the following formula (1) and is also referred to as 4-[2-(dipropylamino)ethyl]-2-indolinone. Ropinirole is known as a dopamine D2 receptor agonist and an oral administration formulation containing ropinirole hydrochloride is in particular effective in treating diseases such as Parkinson's disease and restless legs syndrome.On the other hand, ropinirole may cause side effects ...

ADHESIVE SHEET FOR SKIN PATCH

It is an object of the present invention to provide an adhesive sheet for skin patch, having adhesive force and cohesive force that are practicable as a pharmaceutical product and exhibiting high drug solubility and sufficient drug skin permeability. According to the present invention, provided is an adhesive sheet for skin patch, having an adhesive layer on a support, wherein the adhesive layer comprises, at least, a thermoplastic elastomer and a long-chain branched alcohol having a total carbon number of 13 or more, the long-chain branched alcohol is comprised in an amount of 40 parts by weight or more and 200 parts by weight or less, with respect to 100 parts by weight of the thermoplastic elastomer, and the adhesive layer does not comprise a tackifier, or comprises a tackifier in an amount of 30% by weight or less, with respect to the amount of the entire adhesive layer. 117-. (canceled)18. An adhesive sheet for skin patch , having an adhesive layer on a support , whereinthe adhesive layer comprises, at least, a thermoplastic elastomer and a long-chain branched alcohol having a total carbon number of 13 or more,the long-chain branched alcohol is comprised in an amount of 40 parts by weight or more and 200 parts by weight or less, with respect to 100 parts by weight of the thermoplastic elastomer, andthe adhesive layer does not comprise a tackifier, or comprises a tackifier in an amount of 30% by weight or less, with respect to the amount of the entire adhesive layer.19. The adhesive sheet for skin patch according to claim 18 , which comprises the long-chain branched alcohol in an amount of 50 parts by weight or more and 200 parts by weight or less claim 18 , with respect to 100 parts by weight of the thermoplastic elastomer.20. The adhesive sheet for skin patch according to claim 18 , which comprises the long-chain branched alcohol in an amount of 10% by weight or more claim 18 , with respect to the amount of the entire adhesive layer.21. The adhesive sheet for ...

TRANSDERMAL ABSORPTION PREPARATION

[Problem] To provide a transdermal absorption preparation exhibiting excellent transdermal absorbability for 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide or a pharmaceutically acceptable salt thereof. 1. A transdermal absorption preparation comprisinga support anda rubber-based adhesive layer that is formed on a surface of the support and contains 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide or a pharmaceutically acceptable salt thereof, whereinthe rubber-based adhesive layer further contains oleic acid, capric acid, and crotamiton.2. The transdermal absorption preparation according to claim 1 , wherein the rubber-based adhesive layer further contains a carboxylic acid having 2 to 10 carbon atoms.3. The transdermal absorption preparation according to claim 2 , wherein the carboxylic acid having 2 to 10 carbon atoms is lactic acid.4. The transdermal absorption preparation according to claim 1 , wherein the rubber-based adhesive layer further contains a fatty acid ester having 6 to 20 carbon atoms.5. The transdermal absorption preparation according to claim 4 , wherein the fatty acid ester having 6 to 20 carbon atoms is isopropyl myristate.6. The transdermal absorption preparation according to claim 2 , wherein the rubber-based adhesive layer further contains a fatty acid ester having 6 to 20 carbon atoms.7. The transdermal absorption preparation according to claim 3 , wherein the rubber-based adhesive layer further contains a fatty acid ester having 6 to 20 carbon atoms.8. The transdermal absorption preparation according to claim 6 , wherein the fatty acid ester having 6 to 20 carbon atoms is isopropyl myristate.9. The transdermal absorption preparation according to claim 7 , wherein the fatty acid ester having 6 to 20 carbon atoms is isopropyl myristate. The present invention relates to a transdermal absorption preparation containing 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide or a pharmaceutically acceptable salt thereof as an active ingredient.4-(2- ...

PERCUTANEOUS ABSORPTION PREPARATION

To provide an adhesive skin patch which achieves both of followability to skin expansion and contraction and a bent face and handleability at the time of pasting. 1. A transdermal absorption preparation comprising an adhesive skin patch and a release liner , wherein a backing film containing a knitted fabric and/or a nonwoven fabric,', 'an adhesive layer formed on one surface of the backing film and containing a pharmacologically active substance, and', 'a carrier film heat-sealed on a surface of the backing film opposite to a surface on which the adhesive layer is formed, and released after being applied to an injured part,, 'the adhesive skin patch includes'}the release liner covers at least a part of the adhesive layer of the adhesive skin patch,the carrier film has a bending resistance of 150 mm or less,the backing film has a thickness of 100 μm to 1000 μm, andthe carrier film is a film having an area equal to or narrower than the backing film.2. The transdermal absorption preparation according to claim 1 , wherein a release force of the carrier film from the backing film is larger than a release force of the release liner from the adhesive layer of the adhesive skin patch.3. The transdermal absorption preparation according to claim 1 , wherein a release force of the carrier film from the backing film as measured at a release rate of 300 mm/min in a T-shape release test under conditions of 23° C. and 50 RH is 0.05 N/24 mm to 1 N/24 mm.4. The transdermal absorption preparation according to claim 1 , wherein the carrier film is formed from one or more of thermoplastic resin films.5. The transdermal absorption preparation according to claim 1 , wherein the carrier film is formed from one or more thermoplastic resin films selected from the group consisting of a cyclic olefin copolymer claim 1 , polyethylene claim 1 , polyethylene terephthalate claim 1 , polypropylene claim 1 , an ethylene vinyl alcohol copolymer claim 1 , an ethylene vinyl acetate copolymer claim 1 ...

Transdermal Delivery of Cannabidiol with Other Active Moieties Including Cannabinoids

Transdermal delivery devices for the delivery of cannabidiol (CBD) and related moieties are shown and described. In a reservoir-patch design, a microporous, hydrophilic membrane and a backing define a reservoir that houses a mixture of CBD, a polar liquid, and a gelling agent, along with other moieties that seem to be enhanced or bioavailabilty of increased by the same. The hydrophilic membrane is coated with an amine-compatible silicone skin adhesive. In a monolithic design, a release liner is coated with a mixture of CBD and a PIB or amine-compatible silicone skin adhesive laminated to the backing material. In using CBD as a pure compound or as one to combine with other moieties, the invention is able to control delivery better than the prior art. Construction of the Transdermal patch of reservoir type is also taught, which enables things such as Vitamin B 12 to become part of the complex deliverable by the inventions. 1. A transdermal monolithic patch formulation with CBD in PIB adhesive , from 1% to 30%.2. A transdermal monolithic patch formulation with CBD PIB adhesive with CBD concentration in solid adhesives from 1% to 30% and penetration enhancers in range of 0% to 10%.3. A transdermal patch formulation comprising a reservoir in the shape of a “ravioli” constructed with microporous hydrophilic or hydrophobic membrane on one side and occlusive film on other side.4. A transdermal reservoir patch formulation of claim 3 , further comprising thixotropic alcohol or alcohol/water solution gelled with hydroxyalkyl cellulose containing CBD at high concentration ranging from at least about 1% to 50% CBD.5. A transdermal reservoir patch formulation comprising a reservoir containing thixotropic alcohol or alcohol/water solution gelled with hydroxyalkyl cellulose and containing CBD at a high concentration claim 3 , ranging from 1% to 50% and skin penetration enhancers in a concentration range of 0% to 10%.6. A transdermal patch formulation comprising a reservoir in shape ...

Fentanyl-containing patch for external use

A patch for external use which has a laminate structure comprising a substrate and a pressure-sensitive adhesive layer which contains a styrene/isoprene/styrene block copolymer as the base and further contains a tackifier resin consisting of a rosin resin and at least one other tackifier resin, a softening agent consisting of polybutene and liquid paraffin, a fatty acid ester, and fentanyl, characterized in that the weight ratio of the rosin resin to fentanyl is 1 to 5, the weight ratio of the rosin resin to the whole tackifier resin is 0.1 to 0.6, and the tackifier resin accounts for 30 to 60 wt % of the whole pressure-sensitive adhesive layer. The patch is excellent in the permeation of fentanyl through the skin and in storage stability, and is weak in irritation to skin.

NON-AQUEOUS PATCH

Non-aqueous patches comprising lidocaine, which is not dissolved and is present in a crystalline state, have poor permeability to the skin. Therefore, non-aqueous patches have a high concentration of lidocaine. It is pointed out that lidocaine has an adverse effect on the heart. Prolonged use of a high concentration of lidocaine causes side effects, such as shock, rubor, and irritating sensation. External preparations comprising more than 5 mass % of lidocaine are designated as powerful drugs, and cannot be used as household (nonprescription) medicine. Provided is a non-aqueous patch that is effective to relieve muscle pain, the non-aqueous patch comprising lidocaine and/or its reactant, and a dissolving agent composed of an organic acid and a polyalcohol, which are contained in a base. 17-. (canceled)8. A method of treating pain in an individual in need thereof , comprising applying a non-aqueous patch to the skin of the individual in need thereof , wherein the non-aqueous patch comprises a plaster comprising lidocaine , a dissolving agent , and an elastomer , wherein ,the plaster comprises 0.5 to 7 mass % lidocaine and 1.435 to 9.1 mass % dissolving agent,the dissolving agent comprises dipropylene glycol and isostearic acid, andthe isostearic acid is present in the plaster in an amount of 1.4 to 2.1 mass %.9. The non-aqueous patch according to claim 8 , wherein the elastomer consists of polyisobutylene and styrene isoprene rubber.10. The non-aqueous patch according to claim 8 , wherein the plaster comprises 10 mass % to 40 mass % of the elastomer.11. The non-aqueous patch according to claim 8 , wherein the plaster comprises 20 mass % to 40 mass % of the elastomer.12. The non-aqueous patch according to claim 8 , wherein the plaster further comprises a terpene resin.13. The non-aqueous patch of claim 8 , wherein after application to a human for 12 hours claim 8 , the amount of lidocaine remaining in the non-aqueous patch is 80% or less than the amount prior to ...

TRANSDERMAL HORMONE DELIVERY

Compositions and devices for transdermal hormone delivery are disclosed. The compositions and devices include desogestrel and enable delivery of effective amounts of progestin without the use of skin permeation enhancers. 119-. (canceled)20. A composition for transdermal delivery of a progestin for effecting contraception in a woman , the composition being a polymeric pressure sensitive adhesive (PSA) matrix comprising a polyisobutylene (PIB) PSA , a solubility modifier , and an effective amount of desogestrel , wherein the composition(a) has a solubility for the desogestrel of more than 3% by weight of the composition and up to 10% by weight of the composition;(b) does not comprise a skin penetration enhancer;{'sup': '2', '(c) has a skin-contacting surface area of 5 to 20 cm;'}(d) transdermally delivers a contraceptive amount of the desogestrel when applied to the skin of a woman during a one week wear period; and(e) comprises the desogestrel in an amount of 90% to 100% of its saturation concentration.21. The transdermal composition of claim 20 , wherein the solubility modifier comprises PVP or a PVP/VA copolymer.22. The transdermal composition of claim 21 , wherein the solubility modifier is PVP claim 21 , PVP/VA claim 21 , or a combination of either PVP or PVP/VA with mineral oil.23. The transdermal composition of wherein the PSA is a PIB comprising a mixture of about 10% high molecular weight PIB claim 22 , about 50% low molecular weight PIB claim 22 , and about 40% polybutene.24. The transdermal composition of claim 23 , which comprises (a) 70 to 95 wt % PIB claim 23 , and (b)(i) 1 to 20 wt % mineral oil or 0.1 to 30 wt % PVP or 0.1 to 30 wt % PVP/VA or (ii) 1 to 20 wt % mineral oil and either 0.1 to 30 wt % PVP or 0.1 to 30 wt % PVP/VA.25. The transdermal composition of that comprises 80 to 90 wt % PIB claim 24 , 5 to 15 wt % mineral oil claim 24 , and 0.1 to 10 wt % PVP or PVP/VA.26. The transdermal composition of that has a thickness of 0.1 to 0.6 mm.27. The ...

TRANSDERMAL DELIVERY OF CANNABIDIOL WITH OTHER ACTIVE MOIETIES INCLUDING CANNABINOIDS

Transdermal delivery devices for the delivery of cannabidiol (CBD) and related moieties are shown and described. In a reservoir-patch design, a microporous, hydrophilic membrane and a backing define a reservoir that houses a mixture of CBD, a polar liquid, and a gelling agent, along with other moieties that seem to be enhanced or bioavailability of increased by the same. The hydrophilic membrane is coated with an amine-compatible silicone skin adhesive. In a monolithic design, a release liner is coated with a mixture of CBD and a PIB or amine-compatible silicone skin adhesive laminated to the backing material. In using CBD as a pure compound or as one to combine with other moieties, the invention is able to control delivery better than the prior art. Construction of the Transdermal patch of reservoir type is also taught, which enables things such as Vitamin B 12 to become part of the complex deliverable by the inventions. 1. A transdermal patch comprising a reservoir , the reservoir comprising a solution of cannabidiol (CBD) , the reservoir in the shape of a “ravioli” constructed with a microporous hydrophilic or hydrophobic membrane on one side and occlusive film on other side , the reservoir further comprising thixotropic alcohol or alcohol/water solution gelled with hydroxyalkyl cellulose , the transdermal patch further comprising skin adhesive disposed on the microporous membrane , the transdermal patch further comprising a release liner that is removably contacted on the skin adhesive , further comprising an overlay patch placed over the reservoir.2. A reservoir patch device for the transdermal delivery of cannabidiol and other moieties , comprising , in combination:a backing attached to a hydrophilic, porous membrane to define an enclosed reservoir between the backing and the hydrophilic, porous membrane, wherein the porous membrane has a first side with a skin adhesive and a second side facing the interior of the reservoir;a preparation comprising a ...

TRANSDERMAL SYSTEMS CONTAINING MULTILAYER ADHESIVE MATRICES TO MODIFY DRUG DELIVERY

A transdermal drug-containing dosage unit comprises: a backing layer substantially impervious to the drug to be delivered transdermally; a first polymeric adhesive matrix, in contact with the backing layer, having dispersed therein the drug and having a first delivery profile of the drug; a second polymeric adhesive matrix, in contact with said first polymeric adhesive matrix, having dispersed therein the drug and having a second delivery profile of the drug, wherein said second delivery profile is different from said first delivery profile; and a release liner in contact with the second polymeric adhesive matrix. 147-. (canceled)49. The method of claim 48 , wherein the estrogen comprises estradiol or mono- or di-esters thereof which are transdermally absorbable.50. The method of claim 49 , wherein the estradiol or mono- or di-esters thereof is selected from the group consisting of estradiol-3 claim 49 ,17-diacetate; estradiol-17-acetate; estradiol-3 claim 49 ,17-valerate; estradiol-3-valerate; estradiol-17-valerate; 3-mono-17-mono- and 3 claim 49 ,17-dipilivate esters; 3-mono- claim 49 , 17-mono- claim 49 , and 3 claim 49 ,17-dipropionate esters; ethanol estradiol; estrone; and other estrogenic steroids; and combinations thereof.51. The method of claim 48 , wherein the transdermal drug-containing dosage unit comprises about 0.1% to about 4.0% w/w of estrogen.52. The method of claim 48 , wherein the progestin comprises norethindrone acetate or levonorgestrel.53. The method of claim 48 , wherein the progestin is selected from the group consisting of progesterone claim 48 , medroxyprogesterone acetate claim 48 , ethynodiol diacetate claim 48 , and combinations thereof.54. The method of claim 48 , wherein the transdermal drug-containing dosage unit comprises about 0.1% to about 20% w/w of the progestin.55. The method of claim 48 , wherein one matrix comprises an acrylic adhesive claim 48 , one matrix comprises a polyisobutylene adhesive and one matrix comprises a ...

ROPINIROLE-CONTAINING PATCH AND PACKAGE THEREOF

A ropinirole-containing patch comprises an adhesive agent layer and a support layer, the adhesive agent layer containing ropinirole and/or a pharmaceutically acceptable salt thereof, wherein a content of the ropinirole and/or the pharmaceutically acceptable salt thereof in terms of free ropinirole in the adhesive agent layer satisfies the following two conditions: 1. A ropinirole-containing patch , comprising an adhesive agent layer and a support layer , the adhesive agent layer comprising ropinirole and/or a pharmaceutically acceptable salt thereof ,wherein a content of the ropinirole and/or the pharmaceutically acceptable salt thereof in terms of free ropinirole in the adhesive agent layer satisfies the following two conditions:5 to 13.2% by mass relative to a total mass of the adhesive agent layer; and{'sup': '2', '0.12 to 2.7 mg/cmper unit area of the adhesive agent layer.'}2. The ropinirole-containing patch according to claim 1 , wherein the adhesive agent layer has a mass per unit area of 25 to 200 g/m.3. The ropinirole-containing patch according to claim 1 , which is suitable for treating Parkinson's disease and when administered attains a ropinirole concentration in plasma of 500 to 18000 pg/ml.4. The ropinirole-containing patch according to claim 1 , which is suitable for treating restless legs syndrome and when administered attains a ropinirole concentration in plasma of 125 to 4500 pg/ml.5. The ropinirole-containing patch according to claim 1 , wherein the adhesive agent layer further contains 5 to 50 parts by mass of at least one compound selected from the group consisting of benzyl alcohol claim 1 , oleyl alcohol claim 1 , octyldodecanol claim 1 , and dimethyl isosorbide claim 1 , per 100 parts by mass of the ropinirole and/or the pharmaceutically acceptable salt thereof in terms of free ropinirole.6. The ropinirole-containing patch according to claim 1 , wherein the adhesive agent layer further comprises 10 to 150 parts by mass of at least one compound ...

ADHESIVE PATCH

The present invention provides a patch comprising an adhesive layer on a backing, wherein the adhesive layer contains a adhesive base, a skin irritant drug or a pharmaceutically acceptable salt thereof, and diflucortolone valerate, and the content of the diflucortolone valerate is 0.0009 to 0.08% by mass based on the total mass of the adhesive layer.

Transdermal Therapeutic System Containing Asenapine and Polysiloxane or Polyisobutylene

The present invention relates to a transdermal therapeutic system (TTS) for the transdermal administration of asenapine comprising a self-adhesive layer structure comprising a therapeutically effective amount of asenapine, said self-adhesive layer structure comprising: A) a backing layer; B) an asenapine-containing layer comprising: 1. asenapine in the form of the free base; and 2. a polymer selected from the group consisting of polysiloxanes and polyisobutylenes in an amount of more than 50% by weight based on the total weight of the asenapine-containing layer; and C) optionally an additional skin contact layer.

Anti-Inflammatory and Analgesic Drug for External Use

The present disclosure provides an external preparation comprising lactic acid salt of lidocaine and diclofenac or a salt thereof, wherein lactic acid salt of lidocaine is contained in an amount of 2-5 moles per mole of diclofenac or a salt thereof, which exhibits the improved transdermal absorbability of lidocaine and diclofenac which are active ingredients as well as the skin permeability suitable for clinical use. 1. An external preparation comprising lactic acid salt of lidocaine and diclofenac or a salt thereof , wherein lactic acid salt of lidocaine is contained in an amount of 2-5 moles per mole of diclofenac or a salt thereof.2. The external preparation of claim 1 , wherein the amount of lactic acid salt of lidocaine is 5-40% by weight.3. The external preparation of claim 1 , wherein the amount of diclofenac or a salt thereof is 1-20% by weight.4. The external preparation of claim 1 , further comprising an ester.5. The external preparation of claim 4 , wherein the ester is diethyl sebacate claim 4 , methyl laurate claim 4 , diisopropyl adipate claim 4 , isopropyl myristate claim 4 , propylene carbonate claim 4 , or a mixture thereof.6. The external preparation of claim 1 , which is matrix-type patch preparation (tape preparation).7. The external preparation of claim 6 , wherein an adhesive layer therein comprises a polymer with a dispersed solution comprising lactic acid salt of lidocaine and diclofenac or a salt thereof.8. A process for preparing the external preparation of claim 1 , comprising:mixing lidocaine and lactic acid to provide lactic acid salt of lidocaine which is liquid at ambient temperature; anddissolving diclofenac or a salt thereof into lactic acid salt of lidocaine.9. external preparation of claim 2 , wherein the amount of diclofenac or a salt thereof is 1-20% by weight.10. The external preparation of claim 2 , further comprising an ester.11. The external preparation of claim 3 , further comprising an ester.12. The external preparation of ...

TRANSDERMAL PATCH

The present invention provides a transdermal patch comprising an adhesive layer on a backing, wherein the adhesive layer comprises a drug, DMSO, and an adhesive base, and the adhesive base comprises a styrene-based thermoplastic elastomer having a triblock content of 35% to 65%. 1. A transdermal patch comprising:an adhesive layer on a backing,wherein the adhesive layer contains a drug, DMSO, and an adhesive base, andwherein the adhesive base contains a styrene-based thermoplastic elastomer having a triblock content of 35% to 65%.2. The transdermal patch according to claim 1 ,wherein the adhesive layer has a viscosity of 450 Pa·s to 900 Pa·s at 60° C.3. The transdermal patch according to claim 1 ,wherein the adhesive layer has a melt flow rate of 1.1 to 2 g/10 min at 60° C.4. The transdermal patch according to claim 1 ,wherein the adhesive layer has a loss tangent of 0.53 to 0.8 at 1 Hz.5. The transdermal patch according to claim 1 , which is applied to skin that can extend and contract during motion.6. The transdermal patch according to claim 2 ,wherein the adhesive layer has a melt flow rate of 1.1 to 2 g/10 min at 60° C.7. The transdermal patch according to claim 2 ,wherein the adhesive layer has a loss tangent of 0.53 to 0.8 at 1 Hz.8. The transdermal patch according to claim 3 ,wherein the adhesive layer has a loss tangent of 0.53 to 0.8 at 1 Hz.9. The transdermal patch according to claim 2 , which is applied to skin that can extend and contract during motion.10. The transdermal patch according to claim 3 , which is applied to skin that can extend and contract during motion.11. The transdermal patch according to claim 4 , which is applied to skin that can extend and contract during motion. The present invention relates to a transdermal patch.Dimethyl sulfoxide (DMSO) is an organic solvent having excellent drug solubility, and its use in transdermal patches is being studied. For example, Patent Literature 1 discloses a DMSO-containing transdermal patch that can ...

Dexmedetomidine Transdermal Delivery Devices and Methods for Using the Same

Aspects of the invention include transdermal delivery devices for delivering dexmedetomine to a subject, where the transdermal delivery devices include a single layer matrix dexmedetomine composition. Transdermal delivery devices according to certain embodiments include dexmedetomidine and a pressure sensitive adhesive provided as a single layer formulation. Also provide are methods of using the subject transdermal delivery devices to deliver dexmedetomidine to a subject, as well as kits containing the transdermal delivery devices. 1. A transdermal delivery device comprising: dexmedetomidine; and', 'a pressure sensitive adhesive; and, 'a single layer matrix comprising a dexmedetomidine composition, wherein the dexmedetomidine composition comprisesa backing layer.2. The transdermal delivery device according to claim 1 , wherein the single layer matrix is formulated to deliver a non-sedative amount of dexmedetomidine to a subject over an extended period of time.3. The transdermal delivery device according to claim 1 , wherein the single layer matrix is formulated to deliver a sedative amount of dexmedetomidine to a subject over an extended period of time.4. The transdermal delivery device according to claim 1 , wherein the single layer matrix is formulated to deliver dexmedetomidine to a subject for 6 hours or longer.5. The transdermal delivery device according to claim 1 , wherein the single layer matrix is formulated to deliver dexmedetomidine to a subject for 1 day or longer.6. The transdermal delivery device according to claim 1 , wherein the single layer matrix is formulated to deliver dexmedetomidine to a subject for 7 days or longer.7. The transdermal delivery device according to claim 1 , wherein the amount of dexmedetomidine in the composition is 20% w/w or less.8. The transdermal delivery device according to claim 1 , wherein the amount of dexmedetomidine in the composition is 10% w/w or less.9. The transdermal delivery device according to claim 1 , wherein ...

Methods and Compositions for Transdermal Delivery of a Non-Sedative Amount of Dexmedetomidine

Aspects of the invention include methods for applying to a subject a transdermal delivery device configured to deliver a non-sedative amount of a dexmedetomidine composition. In practicing methods according to certain embodiments, a non-sedative amount of a dexmedetomidine composition is transdermally applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver a non-sedative amount of dexmedetomidine to a subject. Also provided are transdermal delivery devices having a non-sedative amount of dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery devices.

Methods and Compositions for Managing Pain Comprising Dexmedetomidine Transdermal Compositions

Aspects of the invention include methods of managing pain in a subject by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver a pain relieving effective amount of dexmedetomidine to a subject experiencing pain. In practicing methods according to certain embodiments, a transdermal delivery device having a dexmedetomidine composition is applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver an amount of dexmedetomidine effective to manage pain in the subject. Also provided are transdermal delivery devices configured to deliver dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery devices. 1. A method of managing pain in a subject , the method comprising applying to a skin surface of a subject experiencing pain a transdermal delivery device comprising: dexmedetomidine; and', 'a pressure sensitive adhesive; and, 'a dexmedetomidine composition, the dexmedetomidine composition comprisinga backing layer,wherein the dexmedetomidine composition is formulated to deliver a an effective amount of dexmedetomidine to manage pain in the subject.2. The method according to claim 1 , wherein the pain is selected from the group consisting of idiopathic pain claim 1 , acute pain claim 1 , sympathetically mediated pain claim 1 , complex regional pain and neuropathic pain and combinations thereof.3. The method according to claim 2 , wherein the pain is neuropathic pain.4. The method according to claim 3 , wherein the neuropathic pain is associated with sympathetic nervous system.5. (canceled)6. The method according to claim 1 , wherein the subject is a non-sedated subject.7. The method according to claim 6 , wherein the method comprises delivery a non-sedative amount of dexmedetomidine to the subject8. The method according to claim 6 , wherein the method comprises delivering a non-sedative amount of dexmedetomidine to the subject for ...

Methods and Compositions for Treating Withdrawal Syndromes Using Non-Sedative Dexmedetomidine Transdermal Compositions

Aspects of the invention include methods of treating withdrawal syndrome by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver a non-sedative amount of dexmedetomidine to a subject diagnosed as having withdrawal syndrome. In practicing methods according to certain embodiments, a transdermal delivery device having a dexmedetomidine composition is applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver a non-sedative amount of dexmedetomidine to treat withdrawal syndrome in the subject. Also provided are transdermal delivery devices configured to deliver a non-sedative amount of dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery devices. 1. A method of treating a withdrawal syndrome in a subject , the method comprising applying to a skin surface of a non-sedated subject diagnosed as having the withdrawal syndrome a transdermal delivery device comprising: dexmedetomidine; and', 'a pressure sensitive adhesive; and, 'a dexmedetomidine composition, the dexmedetomidine composition comprisinga backing layer,wherein the dexmedetomidine composition is formulated to deliver a non-sedative amount of dexmedetomidine to treat the withdrawal syndrome in the subject.2. The method according to claim 1 , wherein the withdrawal syndrome is selected from the group consisting alcohol withdrawal syndrome claim 1 , benzodiazepine withdrawal syndrome claim 1 , opioid addiction claim 1 , cannabis withdrawal syndrome claim 1 , neonatal withdrawal syndrome claim 1 , nicotine withdrawal syndrome claim 1 , antidepressant withdrawal syndrome.3. The method according to claim 2 , wherein the withdrawal syndrome is opioid addiction.4. The method according to claim 2 , wherein the withdrawal syndrome is alcohol withdrawal syndrome.5. The method according to claim 2 , wherein the withdrawal syndrome is benzodiazepine withdrawal syndrome.6. The ...

Methods and Compositions for Treating Attention Deficit Hyperactivity Disorder, Anxiety and Insomnia Using Dexmedetomidine Transdermal Compositions

Aspects of the invention include methods of treating ADHD, anxiety or insomnia by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver an amount of dexmedetomidine to a subject diagnosed as having ADHD, anxiety or insomnia. In practicing methods according to certain embodiments, a transdermal delivery device having a dexmedetomidine composition is applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver an amount of dexmedetomidine sufficient to treat ADHD, anxiety or insomnia in the subject. Also provided are transdermal delivery devices configured to deliver an amount of dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery devices. 1. A method of treating attention deficit hyperactivity disorder (ADHD) , anxiety or insomnia in a subject , the method comprising: [ dexmedetomidine; and', 'a pressure sensitive adhesive; and, 'a dexmedetomidine composition, wherein the dexmedetomidine composition comprises, 'a backing layer;, 'applying to a skin surface of a subject diagnosed as having ADHD, anxiety or insomnia a transdermal delivery device comprisingin a manner sufficient to deliver dexmedetomidine to the subject to treat ADHD in the subject.2. The method according to claim 1 , wherein the subject is diagnosed as having ADHD.3. The method according to claim 1 , wherein the subject is diagnosed as having anxiety.4. The method according to claim 1 , wherein the subject is diagnosed as having insomnia.5. The method according to claim 1 , wherein the method comprises maintaining the transdermal delivery device in contact with the subject for a duration from 4 hours to 24 hours.67-. (canceled)8. The method according to claim 1 , wherein the subject is a child under the age of 8.9. The method according to claim 1 , wherein the subject is a child under the age of 5.10. The method according to claim 1 , wherein the ...

Transdermal delivery system

The invention relates to transdermal therapeutic system for the transdermal administration of buprenorphine, comprising a buprenorphine-containing self-adhesive layer structure comprising A) a buprenorphine-impermeable backing layer, and B) a buprenorphine-containing pressure-sensitive adhesive layer on said buprenorphine-impermeable backing layer, the adhesive layer comprising a) at least one polymer-based pressure-sensitive adhesive, b) an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof, c) a viscosity-increasing substance in an amount of about 0.1% to about 8% of said buprenorphine-containing pressure-sensitive adhesive layer, and d) a carboxylic acid selected from the group consisting of oleic acid, linoleic acid, linolenic acid, levulinic acid and mixtures thereof, in an amount sufficient so that said analgesically effective amount of buprenorphine is solubilized therein to form a mixture including said viscositiy-increasing substance, and wherein the carboxylic acid-, buprenorphine- and viscosity-increasing substance-containing mixture forms dispersed deposits in the said pressure-sensitive adhesive, and wherein said buprenorphine-containing pressure-sensitive adhesive layer is the skin contact layer.

Methods and Compositions for Treating Attention Deficit Hyperactivity Disorder, Anxiety and Insomnia Using Dexmedetomidine Transdermal Compositions

Aspects of the invention include methods of treating ADHD, anxiety or insomnia by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver an amount of dexmedetomidine to a subject diagnosed as having ADHD, anxiety or insomnia. In practicing methods according to certain embodiments, a transdermal delivery device having a dexmedetomidine composition is applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver an amount of dexmedetomidine sufficient to treat ADHD, anxiety or insomnia in the subject. Also provided are transdermal delivery devices configured to deliver an amount of dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery devices. 1. A method of treating attention deficit hyperactivity disorder (ADHD) , anxiety or insomnia in a subject , the method comprising: [ dexmedetomidine; and', 'a pressure sensitive adhesive; and, 'a dexmedetomidine composition, wherein the dexmedetomidine composition comprises, 'a backing layer;, 'applying to a skin surface of a subject diagnosed as having ADHD, anxiety or insomnia a transdermal delivery device comprisingin a manner sufficient to deliver dexmedetomidine to the subject to treat ADHD in the subject.2. The method according to claim 1 , wherein the subject is diagnosed as having ADHD.3. The method according to claim 1 , wherein the subject is diagnosed as having anxiety.4. The method according to claim 1 , wherein the subject is diagnosed as having insomnia.5. The method according to claim 1 , wherein the method comprises maintaining the transdermal delivery device in contact with the subject for a duration from 4 hours to 24 hours.67-. (canceled)8. The method according to claim 1 , wherein the subject is a child under the age of 8.9. The method according to claim 1 , wherein the subject is a child under the age of 5.10. The method according to claim 1 , wherein the ...

ADHESIVE PATCH

The present invention is a patch comprising a support, and an adhesive layer disposed on at least one surface of the support and formed of an adhesive composition comprising a drug and an adhesive, wherein the drug is cytisine or a salt thereof, and the adhesive composition has an acid value of 10 or less. 16-. (canceled)7. A patch comprising a support , and an adhesive layer disposed on at least one surface of the support and formed of an adhesive composition comprising a drug and an acrylic adhesive ,wherein the drug is cytisine or a salt thereof, and the adhesive composition has an acid value of 10 or less.8. The patch according to claim 7 , wherein a content of cytisine or a salt thereof is 2 to 6% by weight relative to the total weight of the adhesive composition.9. The patch according to claim 7 , wherein the adhesive is a hydroxyl group-containing acrylic adhesive.10. The patch according to claim 8 , wherein the adhesive is a hydroxyl group-containing acrylic adhesive.11. The patch according to claim 7 , wherein the adhesive composition further comprises an absorption enhancer.12. The patch according to claim 8 , wherein the adhesive composition further comprises an absorption enhancer.13. The patch according to claim 9 , wherein the adhesive composition further comprises an absorption enhancer.14. The patch according to claim 10 , wherein the adhesive composition further comprises an absorption enhancer.15. A patch comprising a support claim 10 , and an adhesive layer disposed on at least one surface of the support and formed of an adhesive composition comprising a drug and an rubber adhesive claim 10 ,wherein the drug is cytisine or a salt thereof, and the adhesive composition has an acid value of 10 or less, andwherein the adhesive composition further comprises an organic acid or a salt thereof.16. The patch according to claim 15 , wherein a content of cytisine or a salt thereof is 2 to 6% by weight relative to the total weight of the adhesive composition. ...

Transdermal Delivery System Containing Rotigotine

Transdermal therapeutic system for the transdermal administration of rotigotine containing an therapeutically effective amount of rotigotine base in a self-adhesive layer structure, comprising A) a backing layer, and B) a rotigotine-containing biphasic layer, the bi phasic layer having a) an outer phase having a composition comprising 75% to 100% of a polymer or a polymer mixture, and b) an inner phase having a composition comprising rotigotine base, wherein the inner phase forms dispersed deposits in the outer phase, and wherein the inner phase comprises i. rotigotine base, and ii. a polymer mixture comprising at least two hydrophilic polymers selected from at least two of the polymer groups: —polyvinylpyrrolidones having a K-Value of at least 80, or from 80 to 200, —polyvinylpyrrolidones having a K-Value of less than 80, or from 10 to 79, —copolymers of vinyl caprolactam, vinylacetate and ethylene glycol, —copolymers of vinylpyrrolidone and vinylacetate, —copolymers of ethylene and vinylacetate, —polyethylene glycols, —polypropylene glycols, —acrylic polymers, —modified celluloses, wherein the polymer mixture in the inner phase is present in an amount sufficient so that said rotigotine base forms a solid solution with the polymer mixture in the inner phase, and C) optionally an additional skin contact layer. 2. Transdermal therapeutic system in accordance with claim 1 , wherein said polymer or polymer mixture in the outer phase is a/are hydrophobic polymer(s).3. Transdermal therapeutic system in accordance with or claim 1 , wherein said polymer or polymer mixture in the outer phase is a/are pressure-sensitive adhesive polymer(s) selected from the group of polysiloxanes claim 1 , polyisobutylenes claim 1 , polyacrylates claim 1 , copolymers of styrene and butadiene claim 1 , copolymers of styrene and isoprene.4. Transdermal therapeutic system in accordance with any one of to claim 1 , wherein said polymer or polymer mixture in the outer phase is a/are pressure- ...

PATCH AND METHOD FOR PRODUCING THE SAME

A method for producing a patch including a support layer, and an adhesive agent layer formed on the support layer and including sodium diacetate, a pressure-sensitive adhesive base agent, and asenapine and/or a pharmaceutically acceptable salt thereof. The sodium diacetate is generated from sodium acetate in the presence of the asenapine and/or salt thereof, a content of the asenapine and/or salt thereof in terms of free asenapine in the adhesive agent layer is in range of 3.0 to 20 mg, and when a content of the asenapine and/or salt thereof in terms of free asenapine in the adhesive agent layer is 6.4 mg and the patch is in contact with skin for 24 hours, Cof free asenapine is in range of 0.5 to 6.0 ng/mL and tof free asenapine is in range of 8 to 28 hr. 1. A patch for administering asenapine , comprising:a support layer; andan adhesive agent layer formed on the support layer and comprising sodium diacetate, a pressure-sensitive adhesive base agent, and at least one of asenapine and a pharmaceutically acceptable salt thereof,{'sub': max', 'max, 'wherein the sodium diacetate is generated from sodium acetate in the presence of the asenapine and/or pharmaceutically acceptable salt thereof, a content of the asenapine and/or pharmaceutically acceptable salt thereof in terms of free asenapine in the adhesive agent layer is in a range of 3.0 to 20 mg, and when a content of the asenapine and/or pharmaceutically acceptable salt thereof in terms of free asenapine in the adhesive agent layer is 6.4 mg and the patch is in contact with skin for 24 hours, a Cof free asenapine is in a range of 0.5 to 6.0 ng/mL and a tof free asenapine is in a range of 8 to 28 hr.'}2. The patch according to claim 1 , wherein when the content of the asenapine and/or pharmaceutically acceptable salt thereof in terms of free asenapine in the adhesive agent layer is 6.4 mg and the patch is in contact with skin for 24 hours claim 1 , an AUCof free asenapine is 36 ng·hr/mL or more.3. The patch according ...

Transdermal Delivery Systems

Disclosed are bupivacaine transdermal delivery systems, and related methods. 1. A transdermal delivery system , comprising:a backing layer; and bupivacaine; and', 'sucrose acetate isobutyrate present in an amount effective to reduce a peel force of the transdermal delivery system compared to a peel force of a transdermal delivery system comprising an otherwise identical pressure sensitive adhesive composition that does not comprise sucrose acetate isobutyrate., 'a pressure sensitive adhesive composition, comprising28.-. (canceled)9. A transdermal delivery system comprising:a backing layer, and{'sup': '2', 'a reservoir laminated to the backing layer that comprises bupivacaine in an amount ranging from about 0.1 to about 0.5 mg/cm; and'}wherein the reservoir is adapted to transdermally deliver the bupivacaine from the transdermal delivery system to a subject for a period such that the following mean plasma concentrations are achieved:{'sup': '2', 'a mean plasma concentration, normalized to an initial loading of the transdermal delivery system, ranging from about 0.0003 to about 0.7 cm/L at about 12 hours after initiation of the transdermal delivery; and'}{'sup': '2', 'a mean plasma concentration, normalized to an initial loading of the transdermal delivery system, ranging from about 0.0014 to about 0.4 cm/L at about 24 hours after initiation of the transdermal delivery.'}10. The transdermal delivery system of claim 9 , wherein the reservoir is further adapted to transdermally deliver the bupivacaine from the transdermal delivery system to a subject for a three day period such that the following mean plasma concentrations are achieved: a mean plasma concentration claim 9 , normalized to an initial loading of the transdermal delivery system claim 9 , ranging from about 0.0013 to 0.3 cm/L at about 48 hours after initiation of the transdermal delivery.11. The transdermal delivery system of claim 9 , wherein the reservoir is further adapted to transdermally deliver the ...

Transdermal delivery system comprising buprenorphine

The invention relates to transdermal therapeutic system for the transdermal administration of buprenorphine, comprising a buprenorphine-containing self-adhesive layer structure comprising A) a buprenorphine-impermeable backing layer, and B) a buprenorphine-containing pressure-sensitive adhesive layer on said buprenorphine-impermeable backing layer, the adhesive layer comprising a) at least one polymer-based pressure-sensitive adhesive, b) an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof, and c) a carboxylic acid selected from the group consisting of oleic acid, linoleic acid and linolenic acid, levulinic acid and mixtures thereof, in an amount sufficient so that said analgesically effective amount of buprenorphine is solubilized therein to form a mixture, and the carboxylic acid buprenorphine mixture forms dispersed deposits in the said pressure-sensitive adhesive, wherein said buprenorphine-containing pressure-sensitive adhesive layer is the skin contact layer.

METHOD FOR TREATING OSTEOARTHRITIS

Disclosed is a method for treating osteoarthritis comprising a step of administering a patch to a patient. The patch comprises a backing layer and an adhesive layer laminated on the backing layer, the adhesive layer comprises an adhesive base, diclofenac sodium, dimethyl sulfoxide, and an organic acid, and a content of the organic acid is 6 mass % to 8 mass % with respect to a total mass of the adhesive layer. The patch is applied to an affected part once a day, and a dose of diclofenac sodium per administration is 70 mg to 150 mg. 1. A method for treating osteoarthritis , the method comprising:a step of administering a patch to a patient,wherein the patch comprises a backing layer and an adhesive layer laminated on the backing layer,wherein the adhesive layer comprises an adhesive base, diclofenac sodium, dimethyl sulfoxide, and an organic acid,wherein a content of the organic acid is 6 mass % to 8 mass % with respect to a total mass of the adhesive layer,wherein the patch is applied to an affected part once a day, andwherein a dose of diclofenac sodium per administration is 70 mg to 150 mg.2. The method of claim 1 , wherein an area of the patch is 70 cmto 140 cm.3. The method of claim 1 , wherein a mass of an adhesive mass of the patch is 190 g/mto 240 g/m.4. The method of claim 1 , wherein the osteoarthritis is knee osteoarthritis.5. The method of claim 4 , wherein the patch is alternately applied to inner and outer sides of a knee every day.6. The method of claim 1 , wherein the patch shows a maximum plasma concentration of diclofenac of 19 to 23 ng/mL during a single dose and a time required to reach the maximum plasma concentration of 6 to 18 hours.7. The method of claim 1 , wherein the patch shows an area under plasma drug concentration-time curve of diclofenac of 300 ng·h/mL to 400 ng·h/mL from the time of a single dose to a final time point of concentration measurement.8. The method of claim 1 , wherein the patch shows an area under plasma drug ...

PERMEANT DELIVERY SYSTEM AND METHODS FOR USE THEREOF

Disclosed are a patch, system, and method for delivery of a permeant composition into a subject via at least one formed pathway through a biological membrane of the subject. The patch comprises a matrix, at least one hydrophilic permeant disposed within the matrix, wherein at least a portion of the permeant can dissolve in biological moisture received from the subject, and at least one permeability enhancer disposed within the matrix. Also disclosed are systems and methods for delivery of a permeant composition into a subject via at least one formed pathway through a skin layer of the subject. 163-. (canceled)64. A method for delivering a permeant through a biological membrane of a subject comprising:a) forming one or micropores in the biological membrane; and i) a matrix;', 'ii) at least one hydrophilic permeant disposed within the matrix, wherein at least a portion of the hydrophilic permeant can dissolve in biological moisture received from the subject through said one or more micropores; and', 'iii) at least one permeability enhancer disposed within the matrix., 'b) placing a patch in physical contact with said one or more micropores, wherein said patch comprises65. The method of claim 64 , wherein the one or more micropores are formed using at least one device from the group consisting of: thermal porators claim 64 , mechanical porators claim 64 , laser porators claim 64 , and hydraulic porators.66. The method of claim 64 , wherein the one or more micropores are formed using a heat conducting element placed in substantial physical contact with the biological membrane to deliver sufficient energy to the biological membrane to thermally ablate said biological membrane.67. The method of claim 64 , wherein the one or more micropores are formed using a thin film tissue interface device.68. The method of claim 64 , wherein the hydrophilic permeant is a bioactive agent.69. The method of claim 68 , wherein the bioactive agent is a protein drug.70. The method of claim ...

PERCUTANEOUS ABSORPTION FORMULATION FOR TREATING SLEEP DISORDERS

Disclosed is a percutaneous absorption formulation containing melatonin which is a pharmacologically active substance useful for treating insomniac patients and sleep disorder patients. 1. A percutaneous absorption formulation comprising:(a) a drug-containing adhesive layer which contains melatonin or a pharmaceutically acceptable salt thereof as an active ingredient, and a polymeric adhesive agent;(b) a support layer; and(c) a release layer.2. The percutaneous absorption formulation of claim 1 , wherein the drug-containing adhesive layer further contains a solubilizing agent claim 1 , a crystallization inhibitor claim 1 , a percutaneous absorption enhancer claim 1 , and an antioxidant.3. The percutaneous absorption formulation of claim 2 , wherein the drug-containing adhesive layer contains claim 2 , based on the total weight of the drug-containing adhesive layer claim 2 , 3.0 to 20 wt % of melatonin or the pharmaceutically acceptable salt thereof claim 2 , 1 to 30 wt % of the solubilizing agent claim 2 , 0.05 to 5 wt % of the crystallization inhibitor claim 2 , 1 to 30 wt % of the percutaneous absorption enhancer claim 2 , 0.1 to 5 wt % of the antioxidant claim 2 , and 50 to 94.85 wt % of a polymeric adhesive agent.4. The percutaneous absorption formulation of claim 2 , wherein the solubilizing agent is one or two or more selected from the group consisting of N-methylpyrrolidone claim 2 , dipropylene glycol claim 2 , propylene glycol claim 2 , propylene carbonate claim 2 , ethoxydiglycol claim 2 , diethylene glycol monoethyl ether claim 2 , triacetin claim 2 , triethyl citrate claim 2 , triethanolamine claim 2 , tromethamine claim 2 , bis-Tris claim 2 , aminomethyl propanediol claim 2 , aminoethyl propanediol claim 2 , polyoxyethylene sorbitan monooleate claim 2 , and PEG-8 caprylic/capric glycerides.5. The percutaneous absorption formulation of claim 2 , wherein the crystallization inhibitor for inhibiting crystal formation of the drug is one or two or more ...

Transdermal drug delivery device including an occlusive backing

A transdermal drug delivery system for the topical application of one or more active agents contained in one or more polymeric and/or adhesive carrier layers, proximate to a non-drug containing polymeric backing layer which can control the delivery rate and profile of the transdermal drug delivery system by adjusting the moisture vapor transmission rate of the polymeric backing layer.

Rotigotine-Containing transdermal absorption preparation with improved stability

A method for preparing a transdermal absorption composition includes mixing rotigotine and an antioxidant at a weight ratio of 1:0.0001 to 0.1. A transdermal therapeutic system includes a substrate and a drug-containing adhesive layer disposed on the substrate and including an antioxidant at a weight ratio of 1:0.0001 to 0.1. The method and system of the present invention suppress the crystallization of rotigotine as well as the generation of related substances, thereby increasing the long-term storage stability of a therapeutic product containing rotigotine or related substances. 1. A method for preparing a transdermal absorption composition , the method comprising mixing rotigotine and an antioxidant at a weight ratio of 1:(0.0001-0.1).2. The method of claim 1 , wherein the rotigotine and the antioxidant are mixed at a weight ratio of 1:(0.001-0.1).3. The method of claim 1 , wherein the antioxidant comprises a material selected from the group consisting of tocopherol claim 1 , an ester of tocopherol claim 1 , ascorbic acid claim 1 , ascorbyl palmitate claim 1 , 2 claim 1 ,5-dihydroxybenzoic acid claim 1 , butylated hydroxytoluene claim 1 , butylated hydroxyanisole claim 1 , propyl gallate claim 1 , and some combination thereof.4. The method of claim 1 , wherein the antioxidant comprises a compound selected from the group consisting of ascorbic acid claim 1 , 2 claim 1 ,5-dihydroxybenzoic acid claim 1 , and some combination thereof.5. A transdermal absorption composition prepared by the method of .6. A transdermal therapeutic system comprising:a substrate the drug-containing adhesive layer; anda drug-containing adhesive layer disposed on the substrate and comprising rotigotine and an antioxidant.7. The transdermal therapeutic system of claim 6 , wherein the drug-containing adhesive layer comprises the rotigotine and the antioxidant at a weight ratio of 1:(0.001-0.1).8. The transdermal therapeutic system of claim 6 , wherein the antioxidant comprises a material ...

PATCH AND PACKAGE THEREOF

A patch comprising: 1. A patch comprising:a backing layer; andan adhesive layer, whereinthe adhesive layer contains a mixture of a pharmaceutically acceptable acid addition salt of ropinirole and potassium hydrogen carbonate, andthe mixture contains at least one selected from the group consisting of ropinirole and pharmaceutically acceptable acid addition salts thereof and potassium hydrogen carbonate.2. The patch according to claim 1 , whereinthe mixture further contains a potassium hydrogen carbonate-derived component.3. The patch according to claim 1 , whereina content of the potassium hydrogen carbonate and/or the potassium hydrogen carbonate-derived component in terms of potassium hydrogen carbonate is 0.5 to 3.0 moles relative to a content of 1.0 mole of the ropinirole and/or the pharmaceutically acceptable acid addition salt thereof in terms of ropinirole free form.4. The patch according to claim 1 , whereina content of the ropinirole and/or the pharmaceutically acceptable acid addition salt thereof in terms of ropinirole free form is 7.7 to 20.0% by mass relative to a total mass of the adhesive layer.5. The patch according to claim 1 , whereinthe adhesive layer contains at least one selected from the group consisting of rubber-based adhesives and silicone-based adhesives.6. A package comprising the patch according to enclosed in a packaging container. The present invention relates to a patch, and more particularly to a patch and a package thereof, the patch containing ropinirole and/or a pharmaceutically acceptable salt thereof.Ropinirole is known as a drug useful for the treatment of Parkinson's disease, restless leg syndrome, and the like, and studies have been conducted in recent years on transdermal administration of preparations containing ropinirole and/or a pharmaceutically acceptable salt thereof from the viewpoints of reduction of administration frequency, compliance improvement, ease of administration and discontinuation thereof, and so on.For ...

TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF SOLIFENACIN

The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of solifenacin. 1. A transdermal therapeutic system for the transdermal administration of solifenacin comprising a solifenacin-containing layer structure ,the solifenacin-containing layer structure comprising:A) a backing layer, andB) a solifenacin-containing layer comprising a therapeutically effective amount of solifenacin,wherein the solifenacin-containing layer structure comprises at least one polymer, andwherein the transdermal therapeutic system does not contain a transdermal permeation enhancer selected from the group consisting of a fatty acid ester, a terpene, and a carboxylic acid having 2 to 10 carbon atoms.2. The transdermal therapeutic system according to claim 1 ,wherein the transdermal therapeutic system does not contain a transdermal permeation enhancer selected from the group consisting of a fatty acid ester, a terpene, and a carboxylic acid.3. The transdermal therapeutic system according to claim 1 ,wherein the transdermal therapeutic system does not contain a transdermal permeation enhancer.4. The transdermal therapeutic system according to any one of to claim 1 ,wherein the at least one polymer is selected from the group consisting of a polymer based on polysiloxanes, a silicone acrylic hybrid polymer, a polymer based on polyisobutylenes, a styrene-isoprene-styrene block copolymer, and an acrylate polymer, preferably the at least one polymer is selected from the group consisting of a polymer based on polysiloxanes and a silicone acrylic hybrid polymer.5. The transdermal therapeutic system according to any one of to claim 1 ,wherein the at least one polymer is contained in the solifenacin-containing layer, preferably in an amount of from about 20% to about 99% by weight, more preferably of from about 30% to about 99% by weight, even more preferably of from about 40% to about 99% by weight based on the solifenacin-containing layer.6. The ...

STORAGE STABLE TRANSDERMAL PATCH OF ROTIGOTINE

Disclosed is a transdermal delivery device comprising a backing layer, a release liner, and an adhesive layer between the backing layer and the release liner, the adhesive layer comprising an active agent solubilized in an adhesive matrix, the adhesive matrix comprising a mixture of biocompatible polymers, wherein the active agent is soluble in at least one of the biocompatible polymers. 143-. (canceled)44. A composition for application to the skin comprising a pharmaceutical active agent solubilized in an adhesive matrix , said adhesive matrix comprising a mixture of biocompatible polymers , wherein said pharmaceutical active agent is soluble in each of said mixture of said biocompatible polymers , without the addition of a solvent whereby a solvent-free process can be utilized to produce said adhesive matrix.45. The composition of claim 44 , wherein said active agent is a dopamine agonist.46. The composition of wherein said dopamine agonist is rotigotine.47. The composition of claim 46 , wherein an amount of said rotigotine ranges from 5% to 9% by weight of said composition.48. The composition of wherein said amount ranges from 6% to 7.5% by weight of said composition.49. The composition of claim 44 , wherein said biocompatible polymers are selected from the group consisting of silicones claim 44 , natural and synthetic rubbers claim 44 , polyisobutylene claim 44 , neoprenes claim 44 , polybutadienes claim 44 , polyisoprenes claim 44 , polysiloxanes claim 44 , acrylic adhesives including cross-linked and uncross-linked acrylic copolymers claim 44 , vinyl acetate adhesives claim 44 , polyacrylates claim 44 , ethylene vinyl acetates claim 44 , styrene-isoprene copolymers claim 44 , polyurethanes claim 44 , plasticized weight polyether block amide copolymers claim 44 , and plasticized styrene-rubber block copolymers.50. The composition of claim 44 , wherein said adhesive matrix comprises polyisobutylene and ethylene vinyl acetate.51. The composition of claim 50 , ...

MIRTAZAPINE-CONTAINING TRANSDERMALLY-ABSORBABLE SKIN-ADHESIVE PREPARATION

The purpose is to provide a mirtazapine-containing transdermal patch capable of suppressing deposition of a crystalline component derived from mirtazapine, deterioration in sense of use, and deterioration in adhesiveness to the skin. The transdermal patch contains a support, a drug-containing layer and a release liner, and the drug-containing layer contains mirtazapine and an organic acid. 1. A transdermal patch comprising a support , a drug-containing layer , and a release liner , wherein the drug-containing layer comprises mirtazapine and an organic acid.2. The transdermal patch according to claim 1 , wherein the drug-containing layer comprises 3%-30% of mirtazapine by mass relative to the drug-containing layer.3. The transdermal patch according to claim 2 , wherein the drug-containing layer comprises 5%-25% of mirtazapine by mass relative to the drug-containing layer.4. The transdermal patch according to claim 1 , wherein the organic acid is an organic acid comprising 2 to 18 carbon atoms.5. The transdermal patch according to claim 4 , wherein the organic acid comprising 2 to 18 carbon atoms is at least one selected from the group consisting of glycolic acid claim 4 , citric acid claim 4 , caprylic acid claim 4 , azelaic acid claim 4 , capric acid claim 4 , undecenoic acid claim 4 , lauric acid claim 4 , myristic acid claim 4 , isostearic acid claim 4 , stearic acid claim 4 , oleic acid claim 4 , and lactic acid.6. The transdermal patch according to claim 1 , wherein the drug-containing layer comprises 2%-30% of the organic acid by mass relative to the drug-containing layer.7. The transdermal patch according to claim 1 , wherein the drug-containing layer comprises 3%-24% of the organic acid by mass relative to the drug-containing layer.8. The transdermal patch according to claim 1 , wherein the organic acid is present in the drug-containing layer in an amount of 0.3-11.0 times by mole the amount of mirtazapine.9. The transdermal patch according to claim 8 , ...

Pharmaceutical Patch for Transdermal Administration of Tapentadol

The invention relates to a pharmaceutical patch for transdermal administration of the pharmacologically active ingredient Tapentadol or a physiologically acceptable salt thereof, the patch comprising a surface layer, an adhesive layer which comprises a pressure sensitive adhesive and at least a portion of the total amount of the pharmacologically active ingredient that is contained in the pharmaceutical patch, and a removable protective layer, wherein the adhesive layer is located between the surface layer and the removable protective layer. 1. A pharmaceutical patch for transdermal administration of the pharmacologically active ingredient Tapentadol or a physiologically acceptable salt thereof , the patch comprisinga) a surface layer,b) an adhesive layer which comprises a pressure sensitive adhesive and at least a portion of the total amount of the pharmacologically active ingredient that is contained in the pharmaceutical patch, andc) a removable protective layer,wherein the adhesive layer is located between the surface layer and the removable protective layer.2. The pharmaceutical patch according to claim 1 , wherein the adhesive layer comprises an acrylate- claim 1 , silicone- or styrene block copolymer-based pressure sensitive adhesive.3. The pharmaceutical patch according to claim 1 , wherein the pressure sensitive adhesive contains a polymer which is derived from a monomer composition comprising monomer units having at least one hydroxyl functional group.4. The pharmaceutical patch according to claim 1 , wherein the concentration of the pharmacologically active ingredient in the adhesive layer is within the range of from 1 to 1 claim 1 ,500 g/mand/or within the range of from 1 to 20 wt.-% claim 1 , relative to the total weight of the adhesive layer.5. The pharmaceutical patch according to claim 1 , wherein the pharmacologically active ingredient is Tapentadol in form of its free base.6. The pharmaceutical patch according to claim 1 , wherein the adhesive ...

OPIPRAMOL PATCH

Disclosed herein are compositions that are useful in effecting the transdermal delivery of active agents such as opipramol. More particularly, the disclosed transdermal compositions include an active agent; one or more plasticizers; one or more penetration enhancers; a pressure-sensitive adhesive; and may include one or more hydrophilic polymers. 2. The transdermal drug composition of claim 1 , further comprising a hydrophilic polymer selected from the group consisting of a polymethacrylate polymer and a polyvinylpyrrolidone polymer claim 1 , or a combination thereof.34-. (canceled)5. The transdermal drug composition of claim 1 , wherein the plasticizer is selected from the group consisting of a fatty alcohol claim 1 , a citric acid alkyl ester claim 1 , a glycerol ester claim 1 , phthalic acid alkyl ester claim 1 , a sebacic acid alkyl ester claim 1 , a sucrose ester claim 1 , a sorbitan ester claim 1 , an acetylated monoglyceride claim 1 , a polyol claim 1 , a fatty acid of 4-15 carbons claim 1 , a fatty acid ester claim 1 , a poloxamer claim 1 , a mono- or di-glyceride of edible fats or oils claim 1 , a glyceride claim 1 , a polyethylene glycol (PEG) claim 1 , a sorbitan ester claim 1 , a polysorbate claim 1 , a disaccharide claim 1 , and 2-(2-ethoxyethoxy)ethanol claim 1 , or a combination thereof.6. (canceled)7. The transdermal drug composition of claim 1 , wherein said penetration enhancer is selected from the group consisting of a C-Calcohol or ester claim 1 , a C-Cdiol claim 1 , a C-Cpolyol claim 1 , a fatty alcohol claim 1 , a fatty acid claim 1 , a fatty acid ester claim 1 , a polyoxyethylene fatty acid ester claim 1 , a cyclic or N claim 1 ,N-dimethyl amide claim 1 , a sorbitan monoester claim 1 , a polyethylene glycol ether claim 1 , a biodegradable cyclic urea claim 1 , a polysaccharide claim 1 , a terpene or essential oil claim 1 , a surfactant claim 1 , a sulfoxide claim 1 , and a fatty acid or polyoxyethylene triglyceride claim 1 , or a combination ...

POLYVINYLPYRROLIDONE FOR THE STABILIZATION OF A SOLID DISPERSION OF THE NON-CRYSTALLINE FORM OF ROTIGOTINE

The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof. 1. A method for stabilizing rotigotine , the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine free base , wherein the weight ratio of rotigotine free base to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6.2. The method of claim 1 , wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:4.5.3. A solid dispersion comprising a dispersing agent and a dispersed phase claim 1 , said dispersed phase comprising rotigotine free base and polyvinylpyrrolidone claim 1 , wherein the weight ratio of rotigotine free base to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6.4. (canceled)5. The solid dispersion of claim 4 , wherein the solubility of rotigotine free base in the dispersing agent is below 1 wt-%.6. The solid dispersion of claim 3 , wherein the dispersing agent comprises at least one silicone pressure sensitive adhesive.7. The solid dispersion of claim 3 , wherein the dispersing agent comprises a mixture of a first silicone pressure sensitive adhesive and a second silicone pressure sensitive adhesive and wherein the solid dispersion has a complex viscosity between 5 and 15 MP.8. ...

PLASTER HAVING ADJUSTABLE OCCLUSION

Transdermal or topical plasters containing active ingredient are provided that include a non-occlusive back layer, a matrix formed from of one or more polymer layers having at least one pharmaceutical active ingredient in one or more of the layers, in which the structure-forming base polymers of the layer(s) are non-occlusive or only slightly occlusive and a second polymer that has a low water-vapor permeability and that is immiscible or only very slightly miscible with the base polymer is dispersed in at least one of the polymer layers. 1. A transdermal or topical active ingredient patch having a nonocclusive backing layer which consists of a textile material , a matrix formed from one Or more polymer layers , with at least one active pharmaceutical ingredient in one or more of the layers , wherein the structure-forming base polymers of the layer or layers of the matrix layer which makes contact with the skin on application are nonocclusive or minimally occlusive and are pressure-sensitive adhesives and in at least one of the polymer layers there is a second polymer dispersed , which is immiscible or very minimally miscible with the base polymer and has a low water vapor permeability , which is polyisobutylene , a styrene-isoprene-styrene block polymer or a styrene-butadiene-styrene block polymer , the fraction of dispersed particles of the second polymer being between 7 and 40 wt %.2. The transdermal or topical patch of claim 1 , wherein the pressure-sensitive adhesive is a polyacrylate adhesive.3. The transdermal or topical patch of claim 1 , wherein the pressure-sensitive adhesive is a silicone adhesive.4. The transdermal or topical patch of claim 1 , wherein the pressure-sensitive adhesive is as polyacrylate adhesive or a silicone adhesive and the matrix is single-layer.5. The transdermal or topical patch of claim 1 , wherein the polymer with low water vapor permeability claim 1 , dispersed in the base polymer forms a phase haying an average particle size of 5 ...

External patches containing etofenamate

The present invention provides to patches having excellent skin-permeability and therapeutic effect by the drug with lower irritation. In an external patch in which an adhesive layer containing an adhesive base and a drug are laminated with a backing, the external patch wherein the adhesive base contains 5-50% by weight of synthetic rubber polymer, 10-60% by weight of adhesive resin and 25-60% by weight of liquid paraffin, and the drug is etofenamate. According to the present invention, there is obtainable the patches having excellent skin-permeability and therapeutic effect by the drug with lower irritation.

NON-AQUEOUS PATCH

Non-aqueous patches comprising lidocaine, which is not dissolved and is present in a crystalline state, have poor permeability to the skin. Therefore, non-aqueous patches have a high concentration of lidocaine. It is pointed out that lidocaine has an adverse effect on the heart. Prolonged use of a high concentration of lidocaine causes side effects, such as shock, rubor, and irritating sensation. External preparations comprising more than 5 mass % of lidocaine are designated as powerful drugs, and cannot be used as household (nonprescription) medicine. Provided is a non-aqueous patch that is effective to relieve muscle pain, the non-aqueous patch comprising lidocaine and/or its reactant, and a dissolving agent composed of an organic acid and a polyalcohol, which are contained in a base. 17.-. (canceled)8: A non-aqueous patch comprising a plaster comprising 0.5 to 7 mass % lidocaine , a dissolving agent , and an elastomer , wherein the amount of lidocaine is 196 mg or less and the amount of plaster is 0.84 to 2.8 g , the dissolving agent comprises dipropylene glycol and isostearic acid , and the isostearic acid is present in the plaster in an amount of 1.4 to 2.1 mass %.9: The non-aqueous patch of claim 8 , wherein the elastomer consists of polyisobutylene and styrene isoprene rubber.10: The non-aqueous patch of claim 8 , wherein the plaster comprises 10 mass % to 40 mass % of the elastomer.11: The non-aqueous patch of claim 8 , wherein the plaster comprises 20 mass % to 40 mass % of the elastomer.12: The non-aqueous patch of claim 8 , wherein the plaster further comprises a terpene resin.13: The non-aqueous patch of claim 8 , wherein after application to a human for 12 hours claim 8 , the amount of lidocaine remaining in the non-aqueous patch is 80% or less than the amount prior to application.14: The non-aqueous patch of claim 8 , wherein the amount of lidocaine is 0.1 to 1 mg/cmof the plaster.15: The non-aqueous patch of claim 8 , wherein the lidocaine is ...

TRANSDERMAL ADMINISTRATION OF TAMSULOSIN

In an aspect of the invention, a composition for making a patch for the transdermal delivery of tamsulosin is provided. The composition comprises (a) at least about 1 wt % tamsulosin or a pharmaceutically acceptable salt of tamsulosin, (b) at least about 40 wt % polyisobutylene adhesive or hydrophobic synthetic rubber adhesive, (c) about 1-20 wt % of an aprotic solvent in which tamsulosin dissolves readily, (d) about 1-20 wt % of an unsaturated fatty acid or an alpha-hydroxy acid or a mixture of unsaturated fatty acids or alpha-hydroxy acids or of both unsaturated fatty acids and alpha-hydroxy acids, (e) a lipophilic permeation enhancer, and (f) a matrix modifier. 1. A method for treating a urological condition , comprising:{'sub': 3', '2', 'm, 'providing a transdermal patch comprising an adhesive matrix comprised of polyisobutylene, a solvent selected from dimethylacetamide, n-methylpyrrolidone and dimethylsulfoxide, a mixture of an unsaturated fatty acid and an alpha-hydroxy acid, a permeation enhancer of the formula CH(CH)OCOCHR1R2, where m is an integer in the range of 6 to 14, R1 and R2 are each independently selected from hydrogen, hydroxyl, and a C1-C2 lower alkyl group, wherein at least one of R1 and R2 is hydroxyl or both R1 and R2 are hydrogen, and tamsulosin; and'}{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'administering or instructing to administer the transdermal patch. The method of , wherein the solvent is dimethylsulfoxide.'}32. The method of claim , wherein the adhesive matrix comprises dimethylsulfoxide and tamsulosin in a weight ratio of at least 1.2.4. The method of claim 1 , wherein the adhesive matrix comprises a molar ratio of alpha-hydroxy acid to tamsulosin of at least 0.1.5. The method of claim 1 , wherein the unsaturated fatty acid is selected from the group consisting of oleic acid claim 1 , linoleic acid claim 1 , and linolenic acid.6. The method of claim 1 , wherein the unsaturated fatty acid is a fatty acid with 11 to 21 carbon ...

Transdermal Drug Delivery System

Provided herein is a water- and sweat-resistant transdermal drug delivery system for application to the skin of a mammal that comprises a patch having a diameter between 1 and 8 cm in length and a surface area between 4 and 8 cm. Also provided are methods of producing the transdermal drug delivery system and methods of treatment comprising the use of the transdermal drug delivery system. 1. A method of making a water- and sweat-resistant transdermal drug delivery system , wherein the method comprises first adding a film-forming agent and a plasticizer to water and stirring the mixture at room temperature (25° C.); gradually adding a bioadhesive polymer and a naturally occurring polysaccharide and stir the mixture until the bioadhesive polymer is dissolved and viscosity is reduced; adding a film-forming agent and a keratolytic agent and stirring for 2-5 hours until an even mixture is obtained; adding one or more active agents and stirring the mixture for 1-4 hours to obtain a formulation; casting the formulation onto an array of backing layers; and baking the backing layers at 80° C. for 4-8 hours , thereby making a water- and sweat-resistant transdermal drug delivery system.2. The method of claim 1 , wherein the bioadhesive polymer is chitosan claim 1 , hydroxypropylmethyl cellulose claim 1 , hydroxyethyl cellulose claim 1 , xanthan gum claim 1 , guar gum claim 1 , sodium alginate claim 1 , or a combination thereof.3. The method of claim 1 , wherein the film-forming agent is polyvinyl alcohol claim 1 , polyvinyl pyrrolidone claim 1 , carrageenan claim 1 , gelatin claim 1 , dextrin claim 1 , polyethylene oxide claim 1 , guar gum claim 1 , xanthan gum claim 1 , or a combination thereof.4. The method of claim 1 , wherein the plasticizer is glycerol claim 1 , sorbitol claim 1 , polyethylene glycol claim 1 , polypropylene glycol claim 1 , polyethylene-propylene glycol claim 1 , or a combination thereof.5. The method of claim 1 , wherein the naturally occurring ...

Composition for Patch Preparation Comprising Drug, Organic Solvent, Lipophilic Mass Base, and Powder

The present disclosure provides a composition for a non-aqueous patch preparation with excellent adhesibility which can sustainedly release a drug. The patch preparation can improve the adhesibility of the patch preparation and the release property of a drug by the addition of a powder ingredient the long-time sustention of the adhesibility of tape preparations enables an improvement of the transdermal absorbability and the sustained release of a drug. 1. A composition for a non-aqueous patch preparation comprising a drug , an organic solvent , a lipophilic mass base , and a powder.2. The composition according to claim 1 , wherein the powder is insoluble both in the drug solution in the organic solvent and in the lipophilic mass base.3. The composition according to claim 1 , wherein the powder is at least one selected from the group consisting of crystalline cellulose claim 1 , anhydrous silicic acid claim 1 , starch claim 1 , carmellose claim 1 , carmellose metal salt claim 1 , kaolin claim 1 , agar claim 1 , carrageenan claim 1 , pectin claim 1 , powdered sugar claim 1 , polyethylene powder claim 1 , and polystyrene sulfonate.4. The composition according to claim 1 , wherein the powder is crystalline cellulose.5. The composition according to claim 1 , wherein the organic solvent comprises an ionic liquid.6. The composition according to claim 5 , wherein the ionic liquid is an alkanolamine organic carboxylate.7. The composition according to claim 6 , wherein said organic carboxylic acid is a combination of a higher fatty acid and an organic carboxylic acid having 3 to 7 carbon atoms.8. The composition according to claim 7 , wherein said higher fatty acid is a saturated or unsaturated fatty acid having 10 to 22 carbon atoms.9. The composition according to claim 8 , wherein said saturated or unsaturated fatty acid having 10 to 22 carbon atoms is at least one selected from the group consisting of decanoic acid claim 8 , oleic acid claim 8 , isostearic acid claim 8 , ...

Systems comprising a composite backing and methods for long term transdermal administration

Devices, systems, compositions and methods for long term or prolonged transdermal administration of an active agent are provided.

TRANSDERMAL THERAPEUTIC SYSTEM FOR ADMINISTERING THE ACTIVE SUBSTANCE BUPRENORPHINE

The invention relates to a transdermal therapeutic system for administering the active substance buprenorphine. Said system comprises at least one carboxylic acid that determines the solubility of buprenorphine in the matrix layer and that can likewise be absorbed. The transdermal therapeutic system according to the invention is used in the treatment of pain and characterized by a considerably increased utilization of the active substance. 1. A transdermal therapeutic system for administering buprenorphine to the skin , comprising:an active-ingredient-impermeable backing layer;at least one pressure-sensitive adhesive matrix layer comprising the active ingredient buprenorphine and at least one carboxylic acid;wherein the matrix layer comprises a polymer selected from polysiloxanes or polyisobutylene;wherein the buprenorphine is dissolved in the at least one carboxylic acid to form a solution andwherein the solution is dispersed, in the form of droplets, in the matrix layer.2. The transdermal therapeutic system according to claim 1 , wherein the matrix layer comprises polysiloxane.3. The transdermal therapeutic system according to claim 1 , wherein the polysiloxane is an amine-resistant dimethylpolysiloxane.4. The transdermal therapeutic system according to claim 1 , wherein the polysiloxane is a mixture of an amine-resistant and a non-amine-resistant dimethylpolysiloxane claim 1 , in which the non-amine-resistant dimethylpolysiloxane is present at up to 40% by weight.5. The transdermal therapeutic system according to claim 1 , wherein the matrix layer comprises polyisobutylene.6. The transdermal therapeutic system according to claim 1 , wherein the at least one carboxylic acid diffuses into the skin more quickly than does the active ingredient buprenorphine.7. The transdermal therapeutic system according to claim 1 , wherein the amount of the dispersed solution is up to 40% by weight.8. The transdermal therapeutic system according to claim 1 , wherein the at least ...

PATCH

A patch for administering asenapine includes a support layer, and an adhesive agent layer formed on the support layer and including an adhesive base agent and asenapine and/or a pharmaceutically acceptable salt thereof. The adhesive base agent has a content in a range of 10 to 90% by mass in the adhesive agent layer and includes a natural rubber, polyisobutylene, an alkyl vinyl ether(co)polymer, polyisoprene, polybutadiene, a styrene-butadiene copolymer, a styrene-isoprene copolymer, a styrene-isoprene-styrene block copolymer, or a combination thereof. When a content of the asenapine and/or pharmaceutically acceptable salt thereof in terms of free asenapine in the adhesive agent layer is 3.4 mg, an AUCfor a period starting from the time when the patch is brought into contact with a skin for 24 hours is 27,000 pg·hr/mL or more, and an AUCof an asenapine metabolite is 20% or less of the AUCof the free asenapine. 1. A patch for administering asenapine , comprising:a support layer; andan adhesive agent layer formed on the support layer and comprising an adhesive base agent and at least one of asenapine and a pharmaceutically acceptable salt thereof,{'sub': 2-120', '2-120', '2-120, 'wherein the adhesive base agent has a content in a range of 10 to 90% by mass in the adhesive agent layer and comprises at least one rubber-based adhesive agent selected from the group consisting of a natural rubber, polyisobutylene, an alkyl vinyl ether(co)polymer, polyisoprene, polybutadiene, a styrene-butadiene copolymer, a styrene-isoprene copolymer, and a styrene-isoprene-styrene block copolymer, and when a content of the asenapine and/or pharmaceutically acceptable salt thereof in terms of free asenapine in the adhesive agent layer is 3.4 mg, an AUCfor a period starting from the time when the patch is brought into contact with a skin for 24 hours is 27,000 pg·hr/mL or more, and an AUCof an asenapine metabolite is 20% or less of the AUCof the free asenapine.'}2. The patch of claim 1 , ...

TRANSDERMAL PREPARATION

The present invention provides transdermal absorption preparation having a support, and a drug-containing adhesive layer formed on the support, wherein a drug-containing adhesive layer contains donepezil or a salt thereof, and a higher fatty acid salt. 1. A transdermal absorption preparation comprising a support , and a drug-containing adhesive layer formed on the support , whereinthe drug-containing adhesive layer comprises donepezil or a salt thereof, and a higher fatty acid salt, andthe higher fatty acid salt consists of a salt of a higher fatty acid containing a carbon number of 12 or more and 30 or less.2. The transdermal absorption preparation according to claim 1 , wherein the drug-containing adhesive layer comprises a sodium salt of a higher fatty acid sodium.3. The transdermal absorption preparation according to claim 1 , whereinis the drug-containing adhesive layer comprises a thermoplastic elastomer and liquid paraffin,the content of the liquid paraffin in the drug-containing adhesive layer is more than 300 parts by weight and not more than 1500 parts by weight, per 100 parts by weight of the thermoplastic elastomer, andthe content of the tackifier in the drug-containing adhesive layer is from 0 wt % to not more than 10 wt %.4. The transdermal absorption preparation according to claim 3 , wherein the thermoplastic elastomer is a styrene-based block copolymer.5. The transdermal absorption preparation according to claim 4 , wherein the styrene-based block copolymer is a styrene-isoprene-styrene block copolymer.6. The transdermal absorption preparation according to claim 3 , wherein the drug-containing adhesive layer does not contain a tackifier.7. The transdermal absorption preparation according to claim 6 , wherein the drug-containing adhesive layer contains an ester solvent and an alcohol solvent.8. The transdermal absorption preparation according to claim 1 , wherein the drug-containing adhesive layer contains an ester solvent and/or an alcohol solvent.9 ...

Propynylaminoindan Transdermal Compositions

Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix of the propynylaminoindan in a pressure sensitive adhesive comprising a carboxylated polymer. In some instances, the matrix further includes a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions. 138-. (canceled)39. A method comprising: [ a propynylaminoindan;', 'a pressure sensitive adhesive; and', 'a weak base; and, 'a matrix comprising, 'a backing;, 'applying to a skin surface of a subject a transdermal composition comprisingin a manner sufficient to achieve a constant flux of the propynylaminoindan over an extended period of time.40. The method according to claim 39 , wherein the extended period of time is 72 hours or longer.41. The method according to claim 39 , wherein the propynylaminoindan is N-propargyl-1-aminoindan.42. The method according to claim 41 , wherein N-propargyl-1-aminoindan is present as a free base.43. The method according to claim 42 , wherein the N-propargyl-1-aminoindan is present as a salt.44. The method according to claim 39 , wherein the weak base is a cationic acrylic copolymer.45. The method according to claim 44 , wherein the cationic acrylic copolymer is an aminated methacrylate copolymer.46. The method according to claim 45 , wherein the aminated methacrylate copolymer is a copolymer of diethylaminoethyl methacrylate claim 45 , butyl methacrylate and methyl methacrylate.47. The method according to claim 46 , wherein aminated methacrylate copolymer is substantially the same as Eudragit® E100 aminated methacrylate copolymer.48. The method according to claim 47 , wherein aminated methacrylate copolymer is Eudragit® E100 aminated methacrylate copolymer.49. The method according to claim 39 , wherein the weak base is triethanolamine.50. The method according to claim 39 , wherein the matrix further comprises an enhancer. ...

NON-AQUEOUS PATCH COMPRISING LIDOCAINE

The present invention relates to non-aqueous patches containing lidocaine. 1. A method for treating pain in a patient comprising:administering to the patient a lidocaine tape comprising 1.8 wt % lidocaine such that one or more pharmacokinetic parameters of the lidocaine in the patient is within 70% to 125% of that of an aqueous patch containing 5% lidocaine.2. The method of wherein the one or more pharmacokinetic parameters of the tape is within 80% to 125% of the aqueous patch containing 5% lidocaine.3. The method of wherein one or more pharmacokinetic parameters of the tape is within 90% to 125% of the aqueous patch containing 5% lidocaine.4. The method according to any - wherein the aqueous patch is Lidoderm®.5. The method of wherein the pharmacokinetic parameters are selected from the group consisting of Cand area under the curve last (AUC).6. The method of wherein the pharmacokinetic parameter is C.7. The method of wherein the pharmacokinetic parameter is AUC.8. The method of wherein the pharmacokinetic parameters are Cand area under the curve (AUC).9. A lidocaine containing tape comprising 1.8 wt % lidocaine claim 2 , 5 to 15 wt. % polyisobutylene claim 2 , 0.1 to 0.5 wt. % dibutylhydroxytoluene claim 2 , 10 to 20 wt. % styrene-isoprene-styrene block copolymer claim 2 , 10 to 30 wt. % terpene resin claim 2 , 0.1 to 1 wt. % light anhydrous silicic acid claim 2 , 40 to 55 wt % liquid paraffin claim 2 , 1 to 3 wt. % isostearic acid and 0.1 to 1 wt. % dipropylene glycol.10. The tape of further comprising non-woven cloth backing tape.11. The tape of further comprising a polyethylene terephthalate release liner.12. A method for treating pain in a patient comprising:{'claim-ref': {'@idref': 'CLM-00009', 'claim 9'}, 'administering to the patient the lidocaine tape of such that one or more pharmacokinetic parameters of the formulation is within 70% to 125% of that of an aqueous patch containing 5% lidocaine in an aqueous base which also contains dihydroxyaluminum ...

Naloxone Transdermal Delivery Devices and Methods for Using the Same

Naloxone transdermal delivery devices are provided. Aspects of the naloxone transdermal delivery devices include a matrix comprising a naloxone active agent in a pressure sensitive adhesive and a backing layer. Also provided are methods of making and using the naloxone transdermal delivery devices, as well as kits containing the transdermal delivery devices. The devices, kits and methods of using the same find use in a variety of applications. 1. A transdermal delivery device comprising:a matrix comprising a naloxone active agent in a pressure sensitive adhesive; anda backing layer.2. The transdermal delivery device according to claim 1 , wherein the device is configured to deliver the naloxone active agent to a subject over an extended period of time.3. The transdermal delivery device according to claim 2 , wherein the extended period of time is 1 to 7 days.45-. (canceled)6. The transdermal delivery device according to claim 1 , wherein the amount of naloxone active agent in the matrix adhesive layer is 20% w/w or less.7. (canceled)8. The transdermal delivery device according to claim 1 , wherein the naloxone active agent is naloxone free base.9. The transdermal delivery device according to claim 1 , wherein the device is configured to deliver an amount of the naloxone active agent to a subject at a rate ranging from 0.1 μg/day to 10 claim 1 ,000 μg/day.10. (canceled)11. The transdermal delivery device according to claim 1 , wherein the pressure sensitive adhesive comprises an acrylic polymer claim 1 , acrylate copolymer claim 1 , acrylate-vinyl acetate copolymer or polyacrylonitrile or mixtures thereof.12. The transdermal delivery device according to claim 11 , wherein the pressure sensitive adhesive comprises a non-functionalized polymer.13. The transdermal delivery device according to claim 12 , wherein the pressure sensitive adhesive comprises a non-functionalized acrylate polymer.14. The transdermal delivery device according to claim 1 , wherein the matrix ...

BIODEGRADABLE FREE-STANDING CONTROLLED DRUG RELEASE STICKERS

A multi-layer film useful for controlled drug delivery is described. The multilayer film is peelable and self-supporting. 1. A multilayer film , comprising:a plurality of repeating multilayer units,wherein each multilayer unit comprises at least one conformationally flexible layer comprising a conformationally flexible polyelectrolyte.2. The multilayer film of claim 1 , wherein the conformationally flexible polyelectrolyte is a conformationally flexible polyanion.3. The multilayer film of claim 1 , wherein each multilayer unit further comprises at least one layer comprising a polycation.4. The multilayer film of claim 1 , wherein the multilayer film comprises at least 15 multilayer units.5. The multilayer film of claim 4 , wherein the multilayer film comprises at least 30 multilayer units.6. The multilayer film of claim 1 , wherein a pH of each conformationally flexible layer is less than or equal to 5.0.7. The multilayer film of claim 1 , wherein the multilayer film is self-supporting.8. The multilayer film of claim 3 , wherein the polycation is selected from a polyester claim 3 , a polyanhydride claim 3 , a polyorthoester claim 3 , a polyphosphazene claim 3 , and a polyphosphoester.9. The multilayer film of claim 8 , wherein the polycation is a polyester.10. The multilayer film of claim 9 , wherein the polycation is selected from poly(L-lactide-co-L-lysine) claim 9 , poly(serine ester) claim 9 , poly(4-hydroxy-L-proline ester) claim 9 , and poly[α-(4-aminobutyl)-L-glycolic acid].11. The multilayer film of claim 9 , wherein the polycation is a poly(β-amino ester).13. The multilayer film of claim 1 , wherein each conformationally flexible layer comprises a polymer selected from sodium polystyrene sulfonate claim 1 , hyaluronic acid claim 1 , dextran sulfate claim 1 , alginate claim 1 , poly-L-glutamic acid claim 1 , polyacrylic acid claim 1 , and chondroitin sulfate.14. The multilayer film of claim 1 , wherein each conformationally flexible layer comprises ...